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Omega-3 fatty acids (ω-3 FAs) are an essential fatty acid necessary for healthy development in 
mammals. They possess anti-inflammatory properties and have more recently been shown to 
impact gut microbiota, both factors hypothesized to be associated with depression and anxiety. 
Thus, empirical efforts have begun to examine the benefit of ω-3 FAs as a treatment option for 
various psychological disorders. Although there is evidence that ω-3 FAs have favorable 
outcomes on depressive symptoms, the relationship between ω-3 FAs and anxiety and the 
pathways by which ω-3 FAs produce beneficial health effects are poorly understood. Both 
inflammation and the gut microbiome have an impact in the development of anxiety and 
depression, thus these factors may play a fundamental role as mechanisms explaining the 
beneficial effect of ω-3 FAs on psychological health. This study aims to 1) to examine the cross-
sectional relationship between ω-3 FAs; gut microbiome bacteria and inflammatory markers; and 
stress, anxiety, and depressive symptoms; and 2) to examine if the gut microbiome and 
inflammatory markers mediate the relationship between ω-3 intake and stress, anxiety and 
depressive symptoms. Results indicate that higher levels of omega-3 index and DHA were 
associated with lower reported trait-anxiety symptoms, depressive symptoms, and lower 





inflammation mediated the relationship between ω-3 FAs and stress, anxiety, or depression 
symptoms, but several significant associations were noted. In particular, findings suggest that 
increased omega-3 index and DHA levels predicted fewer trait-anxiety and depression 
symptoms. Additional research is warranted to elucidate the interplay of mechanisms that may 
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CHAPTER 1: INTRODUCTION   
Diet and Mental Health 
One of the most under-recognized factors in the development of mental health disorders 
is the role of nutrition. It is well established that unhealthy dietary habits contribute to negative 
physical health consequences worldwide, and it is estimated that the U.S. Department of 
Agriculture spends millions of dollars annually on nutritional education programs (e.g., The 
Expanded Food and Nutrition Education Program) to improve dietary habits (United States 
Department of Agriculture, 2016). 
In addition to the associated physiological health consequences, accumulating evidence 
supports that diet can play a role in the development, management and prevention of various 
mental health problems such as anxiety and depression. A global meta-analysis showed that 
higher consumption of fruits, vegetables, fish, and grains were associated with lower odds of 
developing depression in adults (Lai et al., 2013). This effect was also found in older adults (≥60 
years) in a cross-sectional study comparing clinically depressed and non-depressed older adults 
(≥60 years) (Payne, Steck, George, & Steffens, 2012).  
The impact of diet on psychological health has also started to be explored in child and 
adolescent populations. A systematic review found a significant association between unhealthy 
diet and poorer mental health outcomes (e.g., depression, anxiety) across seven countries around 
the world (O’Neil et al., 2014). In a recent cross-sectional study of Iranian adolescent girls, those 
whom consumed more pro-inflammatory diets (e.g., high in carbohydrates and unhealthy fats) 
had greater levels of stress (Shivappa, Hebert, & Rashidkhani, 2017). 
Aside from anxiety and depressive symptoms, diet has also been shown to affect other 





cognitive decline (Naqvi et al., 2011), development of subcortical brain structures, and verbal IQ 
(Isaacs et al., 2008). Collectively, these associations have led researchers to investigate the role 
of nutrition and nutritional supplements on treating mental health disorders including depression 
and anxiety. 
Omega-3 Fatty Acids (ω-3 FAs) 
 Omega-3 fatty acids are acknowledged as a necessary component of a healthy lifestyle 
because they possess numerous physical and mental health benefits (Ruxton, Reed, Simpson, & 
Millington, 2007).  
Omega-3 fatty acids (referred to as ω-3 FAs) and omega-6 fatty acids (referred to as ω-6 
FAs), are two major classes of long chain polyunsaturated fatty acids (PUFA) that contain two or 
more double bonds. Each of these PUFAs are essential fatty acids (EFA), meaning they cannot 
be synthesized by mammals and must be obtained by the diet but are physiologically necessary 
for normal mammalian cell functioning (Innis, 1991), including central nervous system 
development (Perica & Delaš, 2011). The essential fatty acid alpha-linolenic acid (ALA) is the 
precursor to the ω-3 FAs, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). The 
essential fatty acid linoleic acid (LA) is the precursor to the ω-6 FA arachidonic acid (AA). A 
balance of ω-3 and ω-6 FAs are necessary for proper health and development (Simopoulos, 
2002).  
The three main ω-3 FAs important to human functioning are: ALA with an 18-carbon 
chain, EPA with a 20-carbon chain, and DHA with a 22-carbon chain. Each of the ω-3 FAs can 
be obtained from dietary sources, ALA from plant-based oils (e.g., seeds, nuts) and EPA and 
DHA from marine based oils (e.g., fish, algae). In addition to obtaining it from dietary sources, 





although this conversion is inefficient (Anderson & Ma, 2009; Burdge & Calder, 2005). Within 
the brain of mammals, DHA is the most common ω-3 FA and plays a critical role in the 
development and function of the brain throughout the life span (Innis, 2007). EPA and DHA 
have both been deemed necessary for healthy brain function and retina development, are a 
protective factor against coronary heart disease and diabetes, and are associated with reduced 
cancer growths (Narayan, Miyashita, & Hosakawa, 2006).  
Over the past century, there has been a drastic shift in dietary patterns, including the 
substantially increased consumption of ω-6 fatty acids, due to the large amount of linoleic acid-
enriched vegetable oils in the food supply, and subsequent deficiency of ω-3 FAs in the Western 
diet (Simopoulos, 2002). The consumption of excessive amounts of ω-6 FAs paired with 
depleted levels of ω-3 FAs in many human diets foster the development of numerous diseases 
such as inflammatory diseases, cancer, and cardiovascular disease (Simopoulos, 2001). In a 
study analyzing risk assessment of dietary risk factors in preventable causes of death in the 
United States, results demonstrate that high dietary trans-fatty acid content, high dietary salt 
content, and low ω-3 FA content were the dietary risks found to have the largest mortality effects 
(Danaei et al., 2009).  
Omega-3 FAs show such promise in improving health that they are being used as a 
treatment option for various inflammatory diseases such as rheumatoid arthritis (James & 
Cleland, 1997), Crohn’s disease (Belluzzi et al., 1996), and asthma (Broughton, Johnson, Pace, 
Liebman, & Kleppinger, 1997). Furthermore, preclinical research has noted a fundamental role 
of ω-3FAs within brain functioning and mental health, in which a lack of these fatty acids in the 
brain can stimulate anxious and depressive behaviors (Müller et al., 2015). Although the 





conditions like depression and anxiety, the pathways by which ω-3 FAs demonstrate beneficial 
effects on mental health is not as well-defined. 
ω-3 FAs and Depression  
A growing literature suggests that ω-3 FA supplementation has therapeutic benefits in 
reducing depressive symptoms. Early findings in rodents indicate that ω-3 FAs play a favorable 
role on depressive behaviors. Rats fed a diet deficient in ω-3 FAs, spent significantly more time 
immobile on the forced swim test for depression compared to rats fed ω-3 adequate diets (DeMar 
et al., 2006; Levant et al., 2008). Furthermore, when rats are supplemented with additional ω-3 
FAs in their diet, they display significantly decreased immobility compared to rats fed a normal 
diet (Ferraz et al., 2008; Huang et al., 2008) indicating ω-3 FA supplementation may assist in 
alleviating depressive behavior in rodents. The literature is mixed when describing the 
associations of ω-3 FAs on depression in human subjects. Data from a health survey of 
Norwegian adults revealed that those who consume cod liver oil which is high in ω-3 FAs were 
less likely to experience depression (Raeder et al., 2007). Similar results were found in pregnant 
English women, where lower ω-3 FA intake was associated with increased depressive symptoms 
(Golding et al., 2009). However, a recent review of 26 studies reports that ω-3 FAs only promote 
a small to moderate difference in depressive symptoms (Appleton et al., 2007). Other researchers 
have discovered more specific findings when examining this relationship. For instance, ω-3 FAs 
may be beneficial to depressive symptoms for males but not females (Murakami et al., 2010). 
Likewise, meta-analyses of experimental studies are also mixed. One meta-analysis examining 
13 randomized placebo-controlled trials found no relationship between depression and ω-3 FAs 
(Bloch & Hannestad, 2012) while another meta-analysis reviewing 13 randomized placebo-





nuanced meta-analysis investigating randomized controlled trials (RCT) of ω-3 FAs as treatment, 
separated patients with a major depressive disorder (MDD) (n = 11) from patients with 
depressive symptoms without a MDD diagnosis (n = 8), and found that ω-3 FAs demonstrated 
clinical benefits as compared to placebo in both MDD groups (Grosso et al. 2014b).   
ω-3 FAs and Anxiety 
The effects of ω-3 FAs on anxiety have been less studied than depression and the 
research is limited to mainly correlational studies, with only a handful of intervention studies in 
human subjects. In the animal literature, ω-3 supplementation has been shown to decrease 
anxiety in non-humans. For instance, a DHA enriched diet has shown to reduce anxiety in mice 
as measured by the light-dark transition test (Carrié et al., 2002), while a diet enriched with EPA 
has shown to decrease anxious behavior (e.g., less time spent in arms of elevated maze) in rats 
(Song, Li, Leonard, & Horrobin, 2003). The impact of ω-3 FAs has also been examined among 
pregnant rats. Pregnant rats assigned to a ω-3 enriched diet displayed decreased anxiety-like 
behavior (e.g., increased time spent in the open arms of the elevated plus maze test) (Chen & Su, 
2012). Another study by Chen & Su (2013) tested whether a diet deficient in ω-3 at either a pre-
weaning stage (embryo-weaning at 3 weeks) as compared to a post-weaning stage (3-10 weeks) 
would lead to anxiety like behaviors in male offspring. It was found that an ω-3 deficient diet 
during the pre-weaning period increased anxiety like behavior in the offspring later in life, as 
compared to the offspring fed the ω-3 deficient diet during the post-weaning stage. These results 
suggest the importance of ω-3 consumption during pregnancy to ensure healthy development and 
to ameliorate anxiety.  
Although limited, within human subjects, findings of observational and experimental 





3 FAs have been shown to have therapeutic benefits for anxiety symptoms in human samples 
(Ross, 2009). Several studies have examined the relationship between ω-3 FAs and anxiety in 
women. In a community-based sample of Australian women, Jacka and colleagues (2013) 
discovered that women with high levels of DHA intake had a 50% reduced likelihood of a 
current anxiety disorder (e.g., panic disorder, agoraphobia, social phobia, specific phobia, 
generalized anxiety disorder). Indeed, pregnant women with lower levels of DHA may have a 
stronger likelihood of having a current anxiety disorder compared to pregnant women with 
higher levels of DHA (Verly-Miguel et al., 2015). In addition, pregnant women who consumed 
diets that included ω-3 FAs were more likely to have lower levels of self-reported anxiety 
symptoms as compared to pregnant women who did not consume any ω-3 FAs in their diet (dos 
Santos Vaz et al., 2013). Further, having an anxiety disorder diagnosis, and the severity of the 
anxiety disorder were associated with the lowest amount of EPA and DHA levels (Liu et al., 
2013). One study investigated the effects of ω-3 FAs on eleven patients diagnosed with 
obsessive-compulsive disorder (OCD). Patients were randomly assigned to receive six weeks of 
a placebo and six weeks of EPA 2 grams, in counterbalanced order (Fux, Benjamin, & Nemets, 
2004). Results demonstrated that as compared to the placebo, supplementing with EPA did not 
produce any differences in anxiety. One explanation for the lack of differences between the 
supplements may be the fact that all participants were stabilized on a selective serotonin reuptake 
inhibitor. Another study found that there were lower concentrations of ω-3 FAs in patients with 
social anxiety disorder and that this was also associated with greater symptom severity compared 
to a control group (Green, Hermesh, Monselise, Marom, Presburger, & Weizman, 2006). While 
few experimental studies have been conducted, the research examining the impact of ω-3 FAs on 





Potential Pathways Mediating the Effect of ω-3 FAs on Depression and Anxiety 
What is Inflammation? 
Inflammation is a biological response to bodily injury or infection and is part of the 
innate immune response (Calder, 2006). The inflammatory response allows immune cells such as 
granulocytes, monocytes, and macrophages to destroy invading pathogens and remove cellular 
debris to prepare for future repair. In addition, the inflammatory response involves a release of 
cytokines, which are proteins produced by monocytes and macrophages to regulate immune and 
inflammatory reactions (Zhang & An, 2009). However, a prolonged or uncontrollable 
inflammatory response can result in tissue damage and lead to inflammatory diseases (Calder, 
2006). 
Importance of Inflammation on Depression and Anxiety  
Mental health and inflammation have shown to be associated with one another, and it has 
been theorized that the release of cytokines as a part of inflammatory response serves a critical 
role in depression (Maes et al., 2009). Depression has been linked to increased production of 
proinflammatory cytokines (e.g., TNF-α, IL-6). Two meta-analyses of cross-sectional studies 
(Dowlati et al., 2010; Howren, Lamkin, Suls, 2009) suggest that inflammatory markers, 
specifically cytokines TNF-α, IL-1, and IL-6, are elevated in depressed patients. Furthermore, a 
meta-analysis of longitudinal studies shows a small but significant effect of C-reactive protein 
(CRP) on depression (Valkanova et al., 2013). One recent study found that subjects with MDD 
not on medication has significantly higher levels of IL-6 and TNF-α compared to control 
subjects (Lindqvist et al., 2017).  
The relationship between inflammation and anxiety has been less studied. However, one 





in dried blood spots significantly predicted not only depression, but also anxiety and stress five 
years later (Das, 2016). Within an adolescent sample it has been found that there is a linear, 
dose-dependent relationship between levels of CRP and percent of adolescents with GAD 
(Khandaker, et al. 2016). Furthermore, the adolescents in the top third of serum CRP levels, were 
five times more likely to develop GAD than those in the bottom third. Adolescents with 
internalizing disorders (e.g., MDD, generalized anxiety disorder (GAD), separation anxiety 
disorder, social anxiety disorder or panic disorder) demonstrate significantly higher IL-6 as 
compared to adolescents without internalizing disorders (da Silva et al., 2017). As evidence 
indicates that the inflammatory process may elicit anxiety and depressive symptoms and 
disorders, it is important to explore novel approaches to analyze this relationship.  
Relationship between ω-3 FAs and Inflammation  
It has been established that ω-3 and ω-6 FAs play a role in inflammation as a meta-
analysis of 68 randomized control trials (RCTs) discovered that ω-3 supplementation was 
associated with reduced levels of tumor necrosis factor alpha (TNF-α), interleukin 6 (IL-6), and 
CRP in healthy participants as well as participants with chronic non-autoimmune diseases and 
chronic autoimmune diseases (Li, Huang, Zheng, Wu, & Li, 2014). ω-3 and ω-6 FAs affect 
inflammation by being metabolized into signaling molecules (Calder, 2006) that include 
prostaglandins, thromboxanes, lipoxins, and leukotrienes (Smith, 1989) as well as protectins, 
resolvins, and maresins (Serhan, Chiang, Dalli, & Levy, 2015). Increased consumption of ω-3 
FAs have been found to suppress the release of proinflammatory eicosanoids and produce anti-






Understanding how ω-3 FAs biologically interact with immune cells will elucidate how 
they produce anti-inflammatory effects. Omega-3 FAs play many roles in immune cell 
functioning such as modifying membrane proteins, modifying membrane composition and 
fluidity of immune cells, influencing gene expression, and producing lipid mediators (Calder, 
2008). Dietary PUFAs undergo a variety of enzymatic reactions before they are converted into 
eicosanoids, or a family of fatty acids that act as local hormones and influence a variety of 
biological functions including cell growth and metabolism (Smith, 1989). However, the long-
chain fatty acids and their functions depend on the PUFA that they originate from. The EFA 
from the ω-6 series, LA (18:2n-6) is converted to the twenty-carbon long chain fatty acid AA 
(20:4n-6) while the EFA from the ω-3 series, ALA (18:3n-3), is converted to the twenty-carbon 
long chain fatty acid EPA (20:5n-3).  
The relationship between ω-3 and ω-6 FAs is not always straightforward. Metabolites of 
the twenty carbon ω-6 FA AA can exert proinflammatory or pro-resolving actions depending on 
the specific metabolite and the context (Calder, 2006; Poorani et al., 2015). Prostaglandin E2, for 
example, contributes not only to the initiation of inflammation (Ricciotti & FitzGerald, 2011) but 
also to the resolution of inflammation by triggering the production of lipoxin A4, another 
metabolite of AA (Chan & Moore, 2010; Poorani et al., 2015). Another twenty carbon ω-6 FA, 
dihomo-γ-linolenic acid (DGLA) inhibits inflammation through its conversion to prostaglandin 
E1. In contrast, the ω-3 FA EPA inhibits the initiation through its conversion to prostaglandin E3 
(Wall, Ross, Fitzgerald, & Stanton, 2010). Moreover, the ω-3 FA DHA promotes the resolution 
of inflammation through its conversion to resolvins, protectins, and maresins which are vital in 
the resolution of inflammatory responses (Serhan, 2007). EPA also generates similar metabolites 





homeostasis and downregulate proinflammatory cytokines (Bannenberg & Serhan, 2010; 
Schwab, Chiang, Arita, & Serhan, 2007).  
Overall, ω-6 FAs contribute both to the initiation, prevention, and resolution of 
inflammation, while ω-3 FAs are more straightforwardly anti-inflammatory and pro-resolution. 
Thus, a balanced ratio of consumption of ω-3 and ω-6 FAs is important. Currently, the western 
diet has a high ω-6 to ω-3 ratio of approximately 20:1, fostering the development of various 
diseases such as cardiovascular disease, obesity, and diabetes (Simopolous, 2016). The ideal 
ratio of ω-6 to ω-3 is 4:1 or 1:1 (Simopoulos, 2008), or somewhere in between. Consumption of 
fewer ω-6 or improving the intake of ω-3 from food or supplements may improve health by 
supporting the proper regulation of inflammation.  
Although the consumption of a balanced ratio of ω-3 and ω-6 FAs is important, the 
measurement and reporting of this metric should be interpreted with caution. Harris (2006) 
reports that a ratio does not allow one to have a clear picture of the absolute value of each of the 
ω-3 and ω-6 FAs. Furthermore, ω-6 FAs have various physiological properties, which some 
contributing to the resolution of inflammation and thus should not be compiled together into a 
ratio with ω-3 FAs (Harris, 2006). 
ω-3 FAs, Inflammation, and Mental Health 
There has been an expansion of empirical research on the mechanisms underlying the 
relationship between ω-3 FAs and depression (Müller et al., 2015; Su, Wang, & Pae, 2013), with 
one hypothesized mechanisms of action being the inflammatory response. See Figure 1.  
Decreased levels of ω-3 FAs have been found to increase the amount of proinflammatory 
cytokines and increase depression and anxiety symptoms. For example, university students with 





compared to controls (Maes, 2000). In addition, adult patients with clinical depression have 
shown to have lower levels of ω-3 FAs and greater levels of inflammatory markers as compared 
to control patients (Baek & Park, 2013). Compared to a control group, women with perinatal 
depression displayed decreased levels of ω-3 FAs and significantly greater levels of TNF-α 
(Chang et al., 2017).  
The impact of ω-3 FAs in relation to inflammatory markers and anxiety symptoms have 
been less studied. Kiecolt-Glaser and colleagues (2011) examined whether ω-3 FAs would 
decrease proinflammatory cytokine (IL-6) and anxiety symptoms in a sample of 68 medical 
students. It was found that the participants who received the ω-3 FA supplements demonstrated a 
14% reduction in stimulated IL-6 and a 20% decrease in anxiety scores as compared to a 
placebo. Although not significant, the authors note that there was a comparable reduction in 
stimulated TNF-α levels as well. 
What is the Gut Microbiome? 
The human gut microbiome is a collection of trillions of microorganisms (e.g., bacteria, 
fungi) that reside in the gastrointestinal tract. Each individual has a unique gut microbiome and 
many factors influence the composition of the gut microbiome including age, sex, and dietary 
habits. The nutritional value of food is influenced by the structure of an individual’s gut 
microbiome, and food in turn shapes the microbiome (Kau et al., 2012). The gut microbiome 
plays a notable role in physical and mental health and alterations within the gut microbiome are 
associated with the development of various chronic conditions. Thus, it is hypothesized that in 
addition to the inflammatory response, the gut microbiome may be a potential mechanism 






Importance of the Gut Microbiome for Depression and Anxiety 
Additionally, developments have been made in the past decade regarding our 
understanding of how the brain communicates with the human gastrointestinal tract. Recent 
research highlights an expanded system: the brain-gut-microbiota axis, which posits that the 
microbiota in the gut also impacts the central nervous system, which in turn influences 
neurological functioning, inflammation, and emotion-related behaviors (Wong et al., 2016).  
Although novel, there is already extensive research on the brain-gut axis and the 
bidirectional relationship between the brain and the gastrointestinal tract (GIT) (Grenham et al., 
2011; Mayer, 2011). Studies of germ-free gnotobiotic mice (where only known strains of 
microorganisms are present) show how essential the gut microbiota is not only to the 
development of a healthy gut, but also to the development of a healthy central nervous system. 
Animal studies show that when experiencing high levels of stress, animals have altered 
microbiome profiles (Bailey et al., 2011; Cryan & Dinan, 2012). Furthermore, clinical studies 
have shown that the administration of the probiotic, Lactobacillus rhamnosus, is associated with 
reduced anxiety- and depressive-like behavior in rats (Bravo et al., 2011). 
These studies have been expanded to human subjects and the gut microbiome appears to 
play a large role in human cognitive and emotional functioning (Dinan, Stilling, Stanton, & 
Cryan, 2015). Adults administered probiotics (Lactobacillus helveticus and Bifidobacterium 
longum) demonstrated improved psychological distress symptoms over a 30-day period 
(Messaoudi et al., 2011). In another human study, infants supplemented with probiotics had no 
diagnosis of Asperger’s Syndrome and/or attention deficit hyperactivity disorder at the age of 13, 
while 17% of children who received placebo formula developed a diagnosis of a developmental 





prevents inflammatory responses which in turn may lead to neuropsychiatric disorders 
(Robertson et al., 2016).  
Effect of ω-3 FAs on the Gut-Microbiome 
Dietary habits have been found to largely influence the structure of the microbiome 
(David et al., 2014; Kau, 2012). Novel evidence has shown that ω-3 FAs have a significant 
impact on gut microbiota (Yu et al., 2014). One study found that mice supplemented with ω-3 
FAs have more anti-inflammatory bacteria (e.g., lactobacillus and Bifidobacterium) compared to 
mice with deficient ω-3 FA (Robertson et al., 2016) as well as decreased levels of inflammation 
and improved gut microbiota profiles (Kaliannan et al., 2015; Myles et al., 2014). Another study 
examining the impact of ω-3 FAs on gut microbiota in early-life stress found that ω-3 FA 
supplementation restored the damaged gut microbiota of maternally separated female rats 
(Pusceddu et al., 2015). Collectively, these findings imply that diet may influence inflammation 
either directly or indirectly through alterations in the gut microbiome, which then may increase 
risk for depression and anxiety.   
Initial studies have examined how ω-3 FAs alter gut microbiota profiles mainly in animal 
samples (e.g., mice, piglets) (Andersen, Mølbak, Thymann, Michaelsen, & Lauritzen, 2011; Yu 
et al., 2014) with limited studies examining human samples (Andersen, Mølbak, Michaelsen, & 
Lauritzen, 2011). Although the relationship between ω-3 FAs and the gut microbiome within 
human samples is relatively unknown, studies are beginning to explore this association. One 
study by Kankaanpää and colleagues (2002) found that probiotic supplemented formula led to 
changes in PUFA composition among infants as compared to infants consuming regular formula. 
For example, Bifidobacterium supplemented formula increased ALA through increased 





mixed results; however, evidence reveals that ω-3 FAs have a therapeutic impact on gut bacteria 
(Li et al., 2011), which may mediate the physical and psychological benefits of ω-3 FA. Further 
investigation of these relationships is warranted within human samples given the implications on 
mental health.  
ω-3FAs, Gut-Microbiota, Inflammation and Mental Health 
Many of the aforementioned studies suggest that ω-3 FAs affect mental health through 
inflammatory responses or the gut-microbiota. However, the literature is beginning to look at the 
dynamic interplay between these variables and how diet plays a critical role in the gut 
microbiome, inflammatory responses, and mental health (Sandhu et al., 2017). One proposed 
hypothesis by Logan and Katzman (2005) is that probiotics and ω-3 FAs may have a 
bidirectional relationship, where ω-3 FAs may alter the types of gut bacteria produced and gut 
bacteria can impact the amount of ω-3 FA levels. Furthermore, researchers have hypothesized 
that the absence of healthy bacteria may lead to the initiation of the inflammatory response, and 
consequently leading to depression (Berk et al., 2013). Based on the literature, it is our scientific 
premise that ω-3 FAs can influence the gut microbiome by increasing healthy gut bacteria and 
subsequently reducing inflammatory cytokines, leading to decreased anxiety and depressive 
symptoms. This hypothesis suggests a serial mediation model can be tested, where the predictor 
exerts an effect on the outcome through two mediators linked in a causal chain (Hayes, 2015). 
Taken together, these pathways have the potential to explain the ways in which ω-3 FAs are 








Quality of Current Research 
The present state of the research involving ω-3 FAs and mental health outcomes 
demonstrate a great amount of heterogeneity. There are at least three important ways that future 
research can test how ω-3 FAs may impact psychological health.  
 Stringent Testing of Dosage and Type of ω-3 FAs 
Each type of ω-3 FA (i.e., ALA, EPA, and DHA) has a different biochemical make-up 
and may have different implications on mental health outcomes over different periods of time. 
Thus, controlling for the specific type of ω-3 FA administered and length of intervention would 
enhance the literature allowing for more specific conclusions to be made. Moreover, studies 
contain a wide range of dosages, although, most studies administer supplements higher than a 
typical (or over the counter) ω-3 supplement which contains approximately 300 mg of EPA and 
DHA combined (Wall et al., 2010). One meta-analysis concluded that when EPA 
supplementation was 200-2200 mg more than DHA, beneficial effects were found in depressive 
symptoms (Sublette, Ellis, Geant, & Mann, 2011). Currently, there are no established guidelines 
reporting the ideal balance of ω-3 dosages for mental health symptoms.  
Assessing Daily Dietary Intake  
While administering ω-3 FAs to participants, intervention studies do not typically assess 
the diet of their subjects. Utilizing food frequency questionnaires or food diaries would provide a 
way to control for what participants consume in addition to the treatment intervention. This 
would increase our understanding of the impact of ω-3 FAs on depression and anxiety, as dietary 
sources contain different amounts of each type of ω-3 FA (Howe, Meyer, Record, & Baghurst, 
2005; Wall et al., 2010). The predominant types of fatty acid consumed on a regular basis 





For instance, dietary intake of ω-3 FAs will vary based on regional location such as a coastal or 
non-coastal region (Al-Numair, Lewis, & Evans, 2005) which can influence research findings.  
Consistent Measurement of Psychological Symptoms or Disorders  
Reviews conducted by Su et al. (2015) and Grosso et al. (2014a) elucidate that meta-
analyses done within this area of research are sensitive to heterogeneity among populations, 
measures, and interventions may not conclude accurate results. However, when the literature 
systematically reviews a homogenous sample, such as patients diagnosed with MDD, results 
strongly show the efficacy of ω-3 FAs on depression. In addition, when looking at studies 
examining ω-3 FAs and anxiety, there are diverse measures of anxiety utilized ranging from 
general anxiety symptoms to more specific anxiety (e.g., test anxiety). It is important to 
accurately assess the type of psychological symptoms since different symptoms may modify the 
effectiveness of ω-3 FAs, and thus would determine the specific patient populations that ω-3 FAs 
would be recommended for.  
Current Project Aims and Hypotheses 
Although there are many advances in modern medicine, the rate of psychiatric illness 
continues to rise. Expanding research efforts to incorporate additional factors that may improve 
psychological health, such as diet, can potentially enhance the development, management and 
prevention of anxiety and depression. Many studies have examined the relationship between ω-3 
FAs and depression and anxiety demonstrating a positive impact on psychological symptoms. 
Yet few studies have examined the potential mechanisms underlying the relationship between ω-
3 FAs and depression and anxiety.  
The present study aims to explore the potential mechanisms underlying the relationship 





mechanisms being inflammation and the gut microbiome. Many of the variables outlined have 
been examined separately in animal and human samples, however, no one study has examined 
the associations between ω-3 intake, gut microbiota functioning, inflammatory markers, and 
stress, anxiety and depression outcomes in a human sample. Given that research has established 
that diet has a considerable impact on both physical and mental health, the present study aims to 
expand the literature by understanding the ways in which these relationships occur. Additionally, 
since this is the first study examining these relationships, paired with evidence that males and 
females exhibit differences in ω-3 levels (Kitson, Stroud, & Stark, 2010) and presentation of gut 
bacteria (Jašarević, Morrison, & Bale, 2016) due to differences in sex hormones; we will recruit 
an all female sample. Elucidating these relationships will shed light onto how dietary intake can 
influence our biological functioning and subsequently, mental health conditions. This 
understanding will, in turn, be able to shape the way we understand how psychological 
conditions develop and can help influence the prevention and treatment of anxiety and 
depression. 
The specific aims for the proposed study are two-fold: 1) To examine the cross-
sectional relationship between ω-3 FAs, gut microbiome bacteria and inflammatory 
markers, and stress, anxiety and depressive symptoms. It is hypothesized that lower ω-3 
intake will be associated with greater stress, anxiety, and depression symptoms. Lower ω-3 
intake will be associated with deceased levels of Lactobacillus and Bifidobacterium and 
increased inflammation (TNF-α, IL-6, IL-8, IL-1β). Deceased levels of Lactobacillus and 
Bifidobacterium and increased inflammation will be associated with greater stress, anxiety, and 
depression symptoms. 2) To examine if the gut microbiome and inflammatory markers 





It is hypothesized that ω-3 intake will have an indirect association with anxiety and depressive 
symptoms through the gut microbiome (Lactobacillus and Bifidobacterium) and inflammatory 





CHAPTER II: METHODOLOGY 
Participant Characteristics  
Healthy adult females ages 18 and older and fluent in English were recruited to 
participate in the present study (N = 79). Participants were students, faculty, and staff from 
Brooklyn College or from the local community. Participants were excluded if they were 
pregnant, have been diagnosed with an inflammatory or endocrine illness, engaged in heavy 
alcohol use (more than two glasses of alcohol per day) or heavy smoking (more than eight 
cigarettes per day), or have been in psychological or psychiatric treatment for less than 6 months. 
 Participant demographic information is presented in Table 1. Participants ages ranged 18 
to 42 years old (M = 21.7, SD = 4.1), the sample was all female, and they identified their 
ethnicity as primarily Black (25.3%), White (24.1%), and Hispanic/Latino (24.1%). The majority 
of participants reported single status (89.9%) and one third were part of a household income less 
than $25,000 (34.2%). More than half of the participants (68.4%) were born via vaginal birth as 
compared to cesarean section (25.3%). Approximately one third of participants (32.9%) reported 
they were fed both breast milk and formula as a baby, one fourth of participants (24.1%) reported 
being breast-fed, and formula-fed (24.1%), and approximately one fifth of participants (17.7%) 
were not sure. The majority of participants are not currently taking an oral contraceptive (87.3%) 
and denied past use of an oral contraceptive (75.9%). 
Descriptive statistics of self- report measures are presented in Table 2. Based on the 
established clinical cutoff scores, 39.2% of participants (n = 31) reported no to minimal 
depressive symptoms, 41.8% of participants (n = 33) reported mild depressive symptoms, 15.2% 
of participants (n = 12) reported moderate depressive symptoms and 3.8% of participants (n = 3) 





Individuals with past oral contraceptive use reported higher stress symptoms on the PSS 
(M = 23.11, SD = 4.81, n = 19) compared to those who have not used oral contraceptives (M = 
19.05, SD = 6.87, n = 60) (t = 2.86, df = 43.15, p = 0.006). No other significant differences were 
noted on self-report measures as a function of ethnicity, marital status, income, method of birth 
(e.g., vaginal or cesarean section), breast fed or formula fed, or current oral contraceptive use.  
Participant’s average ω-3 index, DHA, EPA, and ALA fatty acid percentage values are 
presented in Table 3. No significant differences were noted on the ω-3 index as a function of 
marital status, income, method of birth, breast fed or formula fed, or current or past oral 
contraceptive use. There was a significant effect of ethnicity on DHA percentage values (F 
(5,73) = 6.82, p < 0.001) and ω-3 Index levels (F (5,73) = 6.02, p < 0.001). Post hoc-
comparisons using a Tukey HSD test showed that DHA values for Asian/Pacific Islander 
participants (M = 3.49, SD = 0.66) was significantly higher compared to White (M = 2.23, SD = 
0.56), Hispanic (M = 2.53, SD = 0.69), or Mixed ethnicity (M = 2.24, SD = 0.53) participants. 
DHA levels were also significantly higher in Black participants (M = 2.90, SD = 0.67) compared 
to White participants. Post-hoc comparisons revealed similar findings for ω-3 Index levels where 
the mean was significantly higher for Asian/Pacific Islander participants (M = 5.97, SD = 1.09) 
compared to White (M = 4.32, SD = 0.66), Hispanic (M = 4.70, SD = 0.91), or Mixed ethnicity 
(M = 4.46, SD = 0.80) participants. Omega-3 Index levels were also significantly higher in Black 
participants (M = 5.22, SD = 0.94) compared to White participants (M = 4.32, SD = 0.66). These 
differences in ethnicity were unsurprising as the literature has demonstrated that individuals of 
Asian descent exhibit higher levels of ω-3s than White individuals (Xiao et al., 2016). Similarly, 





FAs (Villegas, Takata, Murff, & Blot, 2016) than White participants or those identifying as 
another ethnicity.  
The mean concentration of each inflammatory marker (IL-1β, IL-6, IL-8, TNF-α) in 
pictograms per milliliter (pg/mL) are presented in Table 3. No significant differences in 
inflammatory markers were noted as a function of marital status, ethnicity, income, method of 
birth, breast fed or formula fed, and current or past oral contraceptive use. 
The average percentages of abundance of gut bacteria (Lactobacillus and 
Bifidobacterium) are presented in Table 3. No significant differences were noted on gut bacteria 
between ethnicity, marital status, income, method of birth, breast fed or formula fed, or current 
or past contraceptive use. A significant effect of income level was noted on Lactobacillus (F 
(6,60) = 2.50, p < 0.03). Post hoc-comparisons using Tukey HSD indicated that the participants 
with a household income of $75,000-$99,999 (M = 5.42, SD = 9.09) has significantly higher 
abundance of Lactobacillus compared to participants with a household income of less than 
$25,000 (M = 0.68, SD = 1.46), $35,000-$49,999 (M = 0.04, SD = 0.08), and $50,000-$74,999 
(M = 0.37, SD = 0.52). It is important to note that this difference in income level could be a type 
I error given that the household income group of $75,000-$99,000 only has three participants. 
Recruitment 
Participants were recruited via flyer postings around the Brooklyn College campus. Study 
information was disseminated via electronic mail to reach Brooklyn College students and faculty 
members. We also used snowball sampling, where existing participants recruited future 
participants, and online advertisement posting websites (e.g., Craig’s list). All participants who 







 Once screened as eligible, participants were scheduled to come to Brooklyn College for 
their assessment. Participants were emailed 24 hours prior to remind them of their appointment 
and of the saliva collection instructions (e.g., do not drink alcohol or smoke 12 hours prior to the 
appointment, and do not eat, drink caffeinated beverages, brush their teeth or use mouthwash one 
hour prior to the appointment). After arriving to the lab, participants completed the informed 
consent procedure with a research assistant. Next participants were asked about saliva-collection-
specific criteria. If the participant has complied, a saliva sample was taken to measure 
inflammatory cytokines. Participants provided a minimum of 0.5ml and up to 2ml of a saliva 
sample. Saliva samples were collected using passive drool, which means that participants were 
asked to drool into a small tube, and used a straw to facilitate saliva collection. Once collected, 
saliva samples were immediately placed into a freezer approximately -20 degrees Celsius until 
they were ready to be analyzed.  
 Next, the dried blood spot sample was collected. Each participant had their sample 
collected by a trained research assistant and materials used were from an individual sealed kit. 
Participants were asked to wash their hands with warm water and hold them at their sides for 20 
seconds to increase circulation to their fingers. A research assistant cleaned the participant’s 
middle or ring finger with an alcohol swab and then used a sterile lancet positioned on the side of 
the finger and pressed firmly until a click was heard and the needle was inserted. Blood was 
collected on the finger and the finger was lightly squeezed to facilitate blood flow. The 
participant's’ finger was pressed on the center of the sample collection card. This was repeated 
until the entire collection circle was filled with blood. Afterwards pressure was applied to the 





minutes the collection card immediately placed into a freezer approximately -20 degrees Celsius 
until they were ready to be analyzed.  
 Following the saliva and blood sample collection, participants completed the self-report 
measures (e.g., demographic history, PSS, STAI, BDI) on a laptop in the research lab. After all 
self-report measures were completed, the research assistant gave the participant a uBiome stool 
sample kit with a unique ID number. Sampling was done privately in a bathroom on campus or 
in their home. Collection of stool sample takes less than two minutes and is a noninvasive 
procedure. Participants were instructed to swab their toilet paper, put the swab in a tube 
provided, and shake the tube for one minute. Then, participants placed their sample in a pre-paid 
return mailer. Once complete, the sample can be stored at room temperature for up to one month, 
however, the participant was instructed to mail out the sample to uBiome by placing in a mailbox 
promptly after collection. Any personal health information that participants provided are 
protected by the uBiome privacy practices; uBiome is required by the Health Insurance 
Portability and Accountability Act of 1996 (HIPAA) to keep all health information confidential. 
Once instructions were discussed and understood participants were given $25 for their 
participation signed a receipt acknowledging their payment. 
Self-Report Measures 
Demographic information collected included: age, gender, race, education level, past and 
present geographic location, food allergies, dietary restrictions, specific amount of smoking and 
alcohol use, whether the participant was born via cesarean section or via vaginal delivery, 
whether the participant was breast fed or formula fed, and past or current treatment for anxiety.  
Perceived Stress Scale (PSS): The PSS is a widely used instrument to assess perceived 





measure assessing the degree in which particular areas in one’s life are perceived as stressful. 
Items are rated on a 5-point Likert scale (0 = never, to 4 = very often). Total PSS scores are 
calculated by reverse-coding four reverse-worded items and then summing across all scale items. 
Total scores can range from 0-40, with higher scores reflecting higher perceived levels of stress. 
The PSS demonstrates good reliability and validity (Siqueira Reis, Ferreira Hino, & Romélio 
Rodriguez-Añez, 2010). The measure had good internal consistency in the present sample (α = 
0.87) on the PSS. 
State-Trait Anxiety Inventory (STAI): Anxiety was measured using the STAI 
(Spielberger, Gorsuch, Lushene, Vagg, & Jacobs, 1983). The STAI is a self-report measure that 
assesses state and trait anxiety in patients. The inventory has 40 questions, 20 assessing state 
anxiety or in a specific situation (STAI-S) and 20 assessing general trait anxiety or a stable 
disposition (STAI-T). Items are rated on a four-point scale (1 = almost never, to 4 = almost 
always) with higher scores indicating greater anxiety. The STAI has shown to be highly reliable 
and valid (Vitasari, Wahab, Herawan, Othman, & Sinnadurai, 2011). The measure demonstrated 
excellent reliability (α = 0.95) in the present sample. 
Beck Depression Inventory (BDI): To assess depressive symptoms, the BDI was 
administered (Beck, Ward, Mendelson, Mock, & Erbaugh, 1961). The BDI is a 21-item self-
report measure that assesses clinical severity of depressive symptoms. There are four possible 
responses for each item ranging from 0-3, depending on intensity. Scores are calculated by 
summing across the 21 items. Total depression scores are categorized as minimal (0–9), mild 
(10–18), moderate (19–29) and severe depression (30–63). The BDI has been found to be a 
reliable and valid measure (Reynolds & Gould, 1981). The BDI had high reliability (α = 0.87) in 





Omega-3 Index & Omega-3 
 Omega-3 FAs was measured via dried blood spot samples from a finger prick using the 
Omega-3 Index Kit provided by and analyzed by Omega Quant Laboratories (OmegaQuant 
Analytics, Sioux Falls, SD). An Omega-3 Index will be calculated which reflects the EPA and 
DHA content of the red blood cells. This will be reported as a percentage of the total identified 
fatty acids in the blood. In addition, a full blood fatty acid profile will be provided with 24 
individual fatty acid values. This method has been previously used in assessing Omega-3 Index 
in patients with depression (Baghai et al., 2011), U.S. servicemen (Johnston, Deuster, Harris, 
MacRae, & Dretsch, 2013) and vegans (Sarter, Kelsey, Schwartz, & Harris, 2015).    
Inflammatory Measurement  
Proinflammatory biomarkers were assessed via salvia sample. Specific biomarkers that 
were measured include TNF-α, IL-6, IL-8, IL-1β. Salvia was collected using passive drool and 
analyzed by Salimetrics Laboratory using enzyme-linked immunosorbent assay (ELISA) 
(Salimetrics, LLC, State College, Pennsylvania). In order to collect the most accurate assessment 
of inflammatory markers, participants were instructed not to drink alcohol or smoke 12 hours 
prior to testing. In addition, they were instructed not to eat, drink caffeinated beverages, brush 
their teeth or use mouthwash one hour prior to testing. The results from each biomarker included 
two reports from each participant and the average in pictograms per milliliter (pg/mL).  
Gut Microbiome 
Levels of gut bacteria, Lactobacillus and Bifidobacterium, were measured from 
participants stool samples. Participants were given a uBiome stool sample kit and provided 
instructions as to how to submit their stool sample. Participants used a sterile cotton swab to 





during transportation. Each kit has a unique Kit ID associated with it and was assigned to a 
participant. Therefore, the participant did not include any identifying information when mailing 
out their fecal sample. Data from the stool sample was collected by uBiome and linked to a 
research account created by the PI. Lactobacillus and Bifidobacterium levels of each participant 
were displayed as a percentage of abundance compared to the general population to determine if 
they are above or below average. 
Statistical Analysis 
 Power analyses were conducted using G Power software (Faul, Erdfelder, Buchner, & 
Lang, 2009). Statistical analysis was conducted in IBM SPSS Statistics Version 25. The goal was 
to have 60 participants complete the current study. We estimated a 20% non-compliance rate 
(e.g., not providing a stool sample), thus, we aimed to recruit a projected estimate of 80 
participants to achieve our goal. A sensitivity power analysis was calculated based on a desired 
power of .80 and the predetermined sample size (Faul, Erdfelder, Lang, & Buchner, 2007). For a 
linear multiple regression with three predictors, based on 60 participants, α = 0.05, and a power 
of .80, a medium effect size (f 2 = 0.19) will be able to be detected. Effect sizes can be classified 
as small (f 2 = 0.02), medium (f 2 = 0.15), or large (f 2 = 0.35). 
 Aim 1: To investigate the cross-sectional associations between ω-3 FAs (EPA/DHA), 
stress, anxiety and depressive symptoms (PSS, STAI, BDI), inflammatory markers (TNF-α, IL-6, 
IL-10) and gut bacteria (Lactobacillus and Bifidobacterium), Pearson correlation analyses will be 
conducted. A Bonferroni correction will be applied, diving alpha by the number of comparisons 
being made, which is used when multiple comparisons occur simultaneously in the one analysis 
to prevent Type I error. Pearson correlation coefficients can be classified as positive or negative, 





0.39), to a moderate relationship (r = 0.40-0.69), to a strong relationship (r = 0.70-0.89), to a 
very strong relationship (r = 0.90-1.00) (Cohen & Holiday, 1982). It is hypothesized there will 
be a negative association between ω-3 intake and stress, anxiety and depressive symptoms (Aim 
1A) given that previous research has found support for this relationship in both animal and 
human subjects (Carrié et al., 2002; Ferraz et al., 2008; Jacka et al.2013; Raeder et al., 2007). It 
is predicted there will also be a negative association between ω-3 intake and inflammation (Aim 
1B). Studies have found decreased levels proinflammatory markers correlated to ω-3FA 
supplementation (Wall, Ross, Fitzgerald, & Stanton, 2010). Furthermore, it is hypothesized there 
will be a positive association between ω-3 intake and levels of Lactobacillus and 
Bifidobacterium (Aim 1C) as studies have shown that ω-3 supplementation is related to 
increased levels of these bacteria mice (Robertson et al., 2016) and supplementation of 
Bifidobacterium was correlated to increased ALA concentration in human infants (Robertson et 
al., 2016). We predict there will be a negative association between Lactobacillus and 
Bifidobacterium and stress, anxiety and depressive symptoms (Aim 1D) since previous studies 
have shown that supplementation of Lactobacillus was associated with decreased anxious and 
depressive behavior in rats (Bravo et al., 2011) and decreased distress symptoms in humans 
(Messaoudi et al., 2011). Lastly, inflammation is hypothesized to have a positive relationship 
with stress, anxiety and depression symptoms (Aim 1E) as studies have demonstrated 
inflammatory markers to be positively associated with anxiety and depressive disorders 
(Khandaker, et al. 2016; Lindqvist et al., 2017). 
 Aim 2: To examine if the gut microbiome and inflammatory markers mediate the 
relationship between ω-3 intake and stress, anxiety and depressive symptoms, we will utilize the 





indirect effects. PROCESS Model 6 was selected to test for serial mediation, where the predictor 
is modeled to exert an effect on the outcome through two mediators linked in a causal chain 
(Hayes, 2015). The bootstrapping resampling method was utilized, using 5000 bootstrap 
samples, this nonparametric method estimates direct and indirect effects and 95% bias-corrected 
confidence intervals and does not assume normality.  
  This study aims to investigate the direct and indirect effects of ω-3 FAs on the three 
dependent variables of stress, anxiety, and depressive symptoms and the mediating role of gut 
bacteria and inflammation. For the present study, stress, anxiety, and depressive scores were 
entered as the outcome variable, measures of ω-3 FAs as the predictor variables, and gut bacteria 
and inflammatory markers as the mediators. To test all combinations of serial mediation, each 
possible combination will be independently run. With four outcome variables (stress, trait-
anxiety, state-anxiety, depression), four predictor variables (ω-3 Index, DHA, EPA, ALA), and 
six mediator variables (Lactobacillus, Bifidobacterium, and TNF-α, IL-6, IL-8, IL-1b) there are 
128 possible mediation analyses (32 separate analyses for each outcome variable).  
The first set of analyses will examine the direct and indirect effects of ω-3 FAs, the 
predictor variable, on stress symptoms, through the two mediators, gut bacteria and inflammation 
(Aim 2A) (Figure 2). The second set of analyses will examine the direct and indirect effects of 
ω-3 FAs on anxiety symptoms, through the mediator’s gut bacteria and inflammation (Aim 2B) 
(Figure 3).  Lastly, the third set of analyses will examine the direct and indirect effects of ω-3 
FAs on depressive symptoms, through the mediator’s gut bacteria and inflammation (Aim 2C) 
(Figure 4). 
Specifically the following relationships will be analyzed in mediation analysis: 1) the 





relationship between ω-3 and gut bacteria, 3) the direct relationship between ω-3 and 
inflammation, 4) the direct relationship between gut bacteria and inflammation, 5) the direct 
relationship between gut bacteria and stress, anxiety, and depression symptoms, 6) the direct 
relationship between inflammation and stress, anxiety, and depression symptoms, 7) the indirect 
relationship between ω-3 and stress, anxiety, and depression symptoms through gut bacteria, 8) 
the indirect relationship between ω-3 and stress, anxiety, and depression symptoms through 
inflammation, and 9) the indirect effect of ω-3 and stress, anxiety, and depression symptoms 
through both gut bacteria and inflammation. We will test whether any demographic variables 
(e.g., race, marital status, income) are significantly related to any outcome variables and if so, 
they will be entered into the model as covariates given that these relationships have not been 
previously examined and these affect dietary intake (Al-Numair, Lewis & Evans, 2005; Darmon 






CHAPTER III: RESULTS 
Normality  
The distributions of study variables were inspected for normality using visual inspection 
and normality tests of skewness, kurtosis, and Shapiro-Wilk values (Appendix X). Normality 
was defined as a skew and kurtosis z-score between -2 and 2 (Bulmer, 1979). Report of 
depression symptoms, state-anxiety symptoms, trait-anxiety symptoms, inflammation data, ω-3 
data, and gut bacteria data were all positively skewed. Both square root and logarithmic 
transformations were conducted (Appendix Y), as these two transformation methods are 
recommended for positively skewed data (Howell, 2007; Tabachnick, & Fidell, 2007). For the 
next section (Aim 1), the nonparametric Spearman rank correlation coefficient was used with 
non-transformed data to examine associations among variable because the data did not meet 
normality assumptions. Once log transformations were conducted, Pearson correlations were 
utilized to examine study variable relationships. The results are presented for both analyses for 
Aim 1.  
Aim 1 (5 hypotheses): Bivariate relationships between ω-3 FAs, gut microbiome bacteria, 
inflammatory markers, and psychological self-report measures. 
For the first hypothesis, the association between ω-3 intake and psychological self-report 
measures (Aim 1A) was examined. There was a negative association between ω-3 index and 
trait-anxiety symptoms (ρ (77) = -0.29, p = 0.01) as well as DHA levels and trait-anxiety 
symptoms (ρ (77) = -0.30, p = 0.01). Contrary to our hypotheses, there was no significant 
relationships between ω-3 intake and any other psychological measure (see Table 4). 
As anticipated, there was a significant negative relationship between ω-3 index and 





0.24, p = 0.03). However, there was no significant relationship between ω-3 intake and other 
inflammatory markers (Aim 1B) (see Table 5). Furthermore, gut bacteria levels were not 
significantly associated with ω-3 intake (Aim 1C) (see Table 6) or psychological self-report 
measures (Aim 1D) (see Table 7). We found a weak positive association between depression 
symptoms and the inflammatory marker IL-1β (ρ (77) = 0.26, p = 0.02) (AIM 1E) (see Table 8). 
No other significant relationships were noted between inflammatory markers and psychological 
self-report measures. 
Log-transformed Correlational Results 
In addition to running Spearman’s correlation, the original data were log transformed to 
allow for the use of Pearson’s correlation to examine study variable relationships. Results using 
Pearson correlations on transformed data were similar to findings for Aim 1A using Spearman 
correlations; there was a negative relationship between trait-anxiety symptoms and both ω-3 
index (r (77) = -0.28, p = 0.01) and DHA levels (r (77) = -0.30, p = 0.01). There was one 
additional finding for Aim 1A, there was a negative association between depression symptoms 
and ω-3 index (r (77) = -0.24, p = 0.03) and DHA levels (r (77) = -0.24, p = 0.03). For the 
remainder of the hypothesized associations, all results were non-significant. Overall, Pearson 
correlation results demonstrate a similar negative relationship between trait-anxiety and both ω-3 
index and DHA. One new association was found between ω-3 index and depressive symptoms. 
There were three associations that were found in the Spearman’s correlation analyses were not 
found when conducting the Pearson’s correlations in that IL-1β was not associated with ω-3 








As a post-hoc analysis, we examined the relationship between gut bacteria and 
inflammation which are the proposed mediating variables. No significant relationships were 
noted between gut bacteria and inflammatory markers (Table 9) using Spearman rank correlation 
or the Pearson correlation after log-transformation. 
 
Aim 2: Serial mediation to test if gut bacteria and inflammatory markers mediate the 
relationship between ω-3 intake and psychological self-report measures 
 Serial mediation models assessed whether gut bacteria and inflammatory markers 
mediated the relationship between ω-3 intake levels and psychological symptoms. Specifically, 
there are four outcome variables for psychological symptoms (stress, trait-anxiety, state-anxiety, 
depression), four predictor variables of ω-3 intake (ω-3 Index, DHA, EPA, ALA), and six 
mediator variables of gut bacteria and inflammatory markers (Lactobacillus, Bifidobacterium, 
and TNF-α, IL-6, IL-8, IL-1β). Each possible combination was independently conducted, 
resulting in 32 analyses for each outcome variable. Mediation results are separated by outcome 
variables, first stress symptoms, next anxiety symptoms including trait- and state-anxiety, and 
lastly depression symptoms. Across all 128 serial mediation analyses conducted, no mediation 
was noted. However, several significant direct effects were detected (see Figure 5 for conceptual 
model and key for direct effects). The findings for each predictor and outcome will be listed 
below, regression coefficients reported are unstandardized.  
  Serial mediation analyses for stress symptoms (Aim 2A). 
Omega-3 Index (predictor) and PSS. Across the eight models assessing the effect of the 





10). IL-1β was positively associated with stress symptoms in the model with Lactobacillus (b = 
0.01, t(63) = 2.33, p = 0.02) and in the model with Bifidobacterium (b = 0.01, t(63) = 2.46, p = 
0.02). In addition, greater abundance of Lactobacillus significantly predicted higher levels of 
inflammatory marker IL-8 (b = 57.96, t(64) = 2.50, p = 0.02). 
DHA (predictor) and PSS. Similar results were found in the models assessing DHA on 
stress symptoms (See Table 11). Higher levels of IL-1β predicted increased stress symptoms 
when Lactobacillus was a mediator (b = 0.01, t(63) = 2.29, p = 0.03) and when Bifidobacterium 
was a mediator (b = 0.01, t(63) = 2.44, p = 0.02). Furthermore, Lactobacillus was positively 
associated with inflammatory marker IL-8 (b = 59.15, t(64) = 2.56, p = 0.01). 
EPA (predictor) and PSS. With EPA as the predictor, seven path coefficients were 
statistically significant (see Table 12). Inflammation was positively associated with stress 
symptoms in four models. IL-1β significantly predicted stress symptoms when Lactobacillus was 
a mediator (b = 0.01, t(63) = 2.49, p = 0.02) and when Bifidobacterium was a mediator (b = 0.01, 
t(63) = 2.61, p = 0.01). Additionally, inflammatory marker IL-6 significantly predicted stress 
symptoms in the models with Lactobacillus (b = 0.24, t(63) = 2.02, p = 0.05) and with 
Bifidobacterium (b = 0.24, t(63) = 2.06, p = 0.04). Lactobacillus was positively associated with 
inflammatory marker IL-8 (b = 57.17, t(64) = 2.41, p = 0.02). In two models, higher levels of 
EPA predicted greater levels of inflammatory marker IL-6 when Lactobacillus was a mediator (b 
= 8.27, t(64) = 2.12, p = 0.04) and when Bifidobacterium was a mediator (b = 7.77, t(64) = 1.98, 
p = 0.05).   
ALA (predictor) and PSS. Serial mediation results with ALA as the predictor were 
similar to the results examining ω-3 index and DHA as the predictor (see Table 13). IL-1β was 





2.59, p = 0.01) and with Bifidobacterium (b = 0.01, t(63) = 2.72, p = 0.01). Furthermore 
Lactobacillus significantly predicted IL-8 (b = 56.78, t(64) = 2.41, p = 0.02).  
Post-hoc Analysis for PSS. Given that participants with past oral contraceptive use 
reported higher stress symptoms compared to participants without past oral contraceptive use, 
serial mediation models for the PSS were recomputed with past oral contraceptive use as a 
covariate.  
Omega-3 (predictor) and PSS with Covariate. Two of the three path coefficients 
remained significant when adding past oral contraceptive use in the model, IL-1β was positively 
associated with stress symptoms in the model with Bifidobacterium (b = 0.01, t(62) = 2.11, p = 
0.04) and greater abundance of Lactobacillus significantly predicted higher levels of 
inflammatory marker IL-8 (b = 56.56, t(63) = 2.40, p = 0.02). Inflammatory marker IL-1β was 
no longer associated with stress symptoms in the model with Lactobacillus. In addition, 
participants with past oral contraceptive use was associated with higher reported stress symptoms 
across five of the eight models assessing ω-3 index on stress symptoms. 
DHA (predictor) and PSS with Covariate. Results were comparable for the models 
assessing DHA on stress symptoms. Two of the three path coefficients remained significant 
when adding past oral contraceptive use in the model, IL-1β was positively associated with stress 
symptoms in the model with Bifidobacterium (b = 0.01, t(62) = 2.09, p = 0.04) and greater 
abundance of Lactobacillus significantly predicted higher levels of inflammatory marker IL-8 (b 
= 57.71, t(63) = 2.45, p = 0.02). Similarly, inflammatory marker IL-1β was no longer 
significantly associated with stress symptoms in the model with gut bacteria Lactobacillus. Past 





EPA (predictor) and PSS with Covariate. With EPA as the predictor, all seven path 
coefficients remained to be statistically significant with past oral contraceptive use was entered 
as a covariate. IL-1β continued to significantly predict stress symptoms when Lactobacillus was 
a mediator (b = 0.01, t(62) = 2.07, p = 0.04) and when Bifidobacterium was a mediator (b = 0.01, 
t(62) = 2.24, p = 0.03). Additionally, inflammatory marker IL-6 continued to significantly 
predict stress symptoms in the models with Lactobacillus (b = 0.24, t(62) = 2.15, p = 0.04) and 
with Bifidobacterium (b = 0.25, t(62) = 2.21, p = 0.03). Lactobacillus remained positively 
associated with inflammatory marker IL-8 (b = 56.02, t(63) = 2.32, p = 0.02). In two models, 
greater levels of EPA predicted higher levels of IL-6 when Lactobacillus was a mediator (b = 
8.23, t(63) = 2.10, p = 0.04) and when Bifidobacterium was a mediator (b = 7.73, t(63) = 1.96, p 
= 0.05). In addition to past oral contraceptive use being associated with increased stress 
symptoms across all eight models, it was noted that past oral contraceptive use predicted 
inflammatory marker IL-1β when Lactobacillus was a mediator (b = 137.29, t(63) = 1.97, p = 
0.05). 
ALA (predictor) and PSS with Covariate. Serial mediation analyses with ALA as the 
predictor and past oral contraceptive use as a covariate led to the same three significant path 
coefficients. IL-1β was positively associated with stress symptoms in the model with 
Lactobacillus (b = 0.01, t(62) = 2.15, p = 0.04) and with Bifidobacterium (b = 0.01, t(62) = 2.32, 
p = 0.02). Furthermore, Lactobacillus significantly predicted IL-8 (b = 56.00, t(63) = 2.34, p = 
0.02). Additionally, past oral contraceptive use being associated with increased stress symptoms 
across six of the eight models, and past oral contraceptive use predicted inflammatory marker IL-





Summary for PSS. Four ω-3FA variables (ω-3-index, DHA, EPA, ALA) were tested as 
predictors of stress symptoms (PSS) in a total of 32 serial mediation models (eight per predictor). 
Across these models, ω-3FAs did not predict stress symptoms. However, several consistent 
patterns emerged; higher levels of IL-1β predicted more reported stress symptoms and greater 
abundance of the gut bacteria Lactobacillus significantly predicted higher levels of the 
inflammatory marker IL-8. In the models with EPA as the predictor, EPA was positively 
associated with IL-6 and IL-6 was positively associated with stress symptoms, however there 
was not a significant indirect effect of IL-6 on the relationship between EPA and stress 
symptoms. Furthermore, when past oral contraceptive use was entered as a covariate, past oral 
contraceptive use predicted higher levels of reported stress symptoms across 23 of the 32 serial 
mediation models. Lastly, there was a positive association between past oral contraceptive use 
and inflammatory marker IL-1β in two models.  
 
  Serial mediation analyses for trait-anxiety symptoms (Aim 2B). 
Omega-3 Index (predictor) and STAI-Trait. The direct effect of ω-3 levels on trait-
anxiety symptoms, without the influence of the mediators, was significant (see Table 14). The 
total effect of ω-3 levels on trait-anxiety symptoms was significant (b = –3.62, t(65) = –2.73, p = 
0.01), which is the sum of the direct and indirect effects of the model. Omega-3 index predicted 
less trait-anxiety symptoms. One path coefficient was noted to be significant, Lactobacillus was 
positively associated with inflammatory marker IL-8 (b = 57.96, t(64) = 2.50, p = 0.02). 
DHA (predictor) and STAI-Trait. With DHA as the predictor, results were similar to ω-3 
index results described above. The total effect of DHA on trait-anxiety symptoms was significant 





symptoms across all eight models (see Table 15). In addition, greater abundance of Lactobacillus 
predicted higher levels of inflammatory marker IL-8 (d) (b = 59.15, t(64) = 2.56, p = 0.01).  
EPA (predictor) and STAI-Trait. With EPA as the predictor, three path coefficients were 
statistically significant (see Table 16). In two models, higher levels of EPA predicted higher 
levels of the inflammatory marker IL-6, when Lactobacillus was entered as a mediator (b = 8.27, 
t(64) = 2.12, p = 0.04) as well as when Bifidobacterium was entered as a mediator (b = 7.77, 
t(64) = 1.98, p = 0.05). Additionally, Lactobacillus was positively associated with inflammatory 
marker IL-8 (d) (b = 57.17, t(64) = 2.41, p = 0.02). 
ALA (predictor) and STAI-Trait. Greater abundance of Lactobacillus predicted higher 
levels of inflammatory marker IL-8 (b = 56.78, t(64) = 2.41, p = 0.02) when ALA was the 
predictor (see Table 17).   
Omega-3/DHA/EPA/ALA (predictor) and STAI-State. All serial mediation results for 
the state-anxiety outcome demonstrated the same significant path coefficients as the trait-anxiety 
results with the exception of the direct and total effects which were not significant. Specifically, 
greater abundance of Lactobacillus was positively associated with inflammatory marker IL-8 
when ω-3 was the predictor (b = 57.96, t(64) = 2.50, p = 0.02), when DHA was the predictor (b = 
59.15, t(64) = 2.56, p = 0.01), when EPA was the predictor (b = 57.17, t(64) = 2.41, p = 0.02) 
and when ALA was the predictor (b = 56.78, t(64) = 2.41, p = 0.02). Additionally, higher levels 
of EPA predicted higher levels of the inflammatory marker IL-6, when Lactobacillus was entered 
as a mediator (b = 8.27, t(64) = 2.12, p = 0.04) as well as when Bifidobacterium was entered as a 
mediator (b = 7.77, t(64) = 1.98, p = 0.05). 
Summary for STAI-Trait and STAI-State. Taken together, across the 64 serial mediation 





anxiety symptoms (STAI-Trait and STAI-State) there was a direct and total effect of ω-3 index and 
DHA predicting less trait-anxiety symptoms but not state-anxiety symptoms. It was consistently 
found that greater abundance of Lactobacillus predicted higher levels of inflammatory marker 
IL-8 and higher levels of EPA predicted greater levels of IL-6 across all serial mediation models 
with trait- and state-anxiety symptoms as the outcome.  
 
Serial mediation analyses for depression symptoms (Aim 2C). 
Omega-3 Index (predictor) and BDI. A significant direct effect of ω-3 index on 
depression symptoms was detected in five of the eight models (see Table 18), in that ω-3 index 
predicted lower depression symptoms without the influence of the mediators. In addition, there 
was a significant total effect of the model (b = –1.87, t(65) = –2.10, p = 0.04), taking into 
account the direct and indirect effects of the model. Lastly, greater abundance of Lactobacillus 
significantly predicted higher levels of the inflammatory marker IL-8 (b = 57.96, t(64) = 2.50, p 
= 0.02). 
DHA (predictor) and BDI. Two models were noted to show a significant direct effect of 
DHA on depression symptoms (see Table 19), where DHA predicted less depression symptoms, 
without taking into account the mediators. The total effect of DHA on depression symptoms was 
significant (b = –2.40, t(65) = –1.97, p = 0.05), taking the sum of the direct and indirect effects of 
the model. Additionally, one path coefficient was noted to be statistically significant in that 
greater Lactobacillus abundance significantly predicted higher levels of IL-8 (b = 59.15, t(64) = 
2.56, p = 0.01). 
EPA (predictor) and BDI. With EPA as the predictor, three path coefficients were 





models, higher levels of EPA predicted higher levels of the inflammatory marker IL-6, once 
when Lactobacillus was a mediator (b = 8.27, t(64) = 2.12, p = 0.04) and when Bifidobacterium 
was a mediator (b = 7.77, t(64) = 1.98, p = 0.05). In addition, Lactobacillus significantly 
predicted higher levels of IL-8 (b = 57.17, t(64) = 2.41, p = 0.02).  
ALA (predictor) and BDI. Only one path coefficient was significant (see Table 21) with 
ALA as the predictor; Lactobacillus was positively associated with inflammatory marker IL-8 (b 
= 56.78, t(64) = 2.41, p = 0.02).  
Summary for BDI. Four ω-3FA variables (ω-3-index, DHA, EPA, ALA) were tested as 
predictors of depressive symptoms (BDI) in a total of 32 serial mediation models. Across all 
models, there was a significant total effect of ω-3 index and DHA predicting depressive 
symptoms. For five models when ω-3 index was the predictor, and two models when DHA was 
the predictor, there was a negative association with depression symptoms. There were some 
consistencies in the findings, specifically, when Lactobacillus and inflammatory markers IL-6 or 
TNF-α were mediators, a direct effect was noted. Collectively, across all 32 serial mediation 
models with depression symptoms as the outcome, Lactobacillus significantly predicted higher 
levels of inflammatory marker IL-8 and EPA significantly predicted higher levels of 
inflammatory marker IL-6.  
 
Global Summary of Mediation Analyses. 
Within the 128 serial mediation models conducted, several patterns were detected. When 
examining anxiety symptoms, there was a direct and total effect of ω-3 index and DHA 
predicting less trait-anxiety symptoms, however, there was no significant effect for state-anxiety 





where ω-3 index and DHA predicted fewer depression symptoms. Gut bacteria and inflammation 
were not found to mediate the relationship between ω-3 intake and stress, anxiety, or depression 
symptoms. Consistently across all models, greater abundance of the gut bacteria Lactobacillus 
predicted higher levels of inflammatory marker IL-8 and EPA significantly predicted higher 
levels of inflammatory marker IL-6. Furthermore, inflammatory markers IL-1β and IL-6 were 







CHAPTER IV: DISCUSSION 
The impact of nutrition on psychological health and cognitive functioning is a growing 
topic of interest among researchers (Gomez-Pinilla, 2008). As mental health disorders continue 
to rise globally, there is promising research supporting the importance of diet as a favorable 
therapeutic option for managing psychological well-being, specifically ω-3 FAs. It has been well 
established that ω-3 FAs are necessary for healthy mammalian central nervous system 
development (Innis, 1991; Perica & Delaš, 2011), and more recently have been recognized to 
play a favorable role on mental health symptoms (Golding et al., 2009; Ross, 2009). 
With increasing interest in understanding the impact of ω-3 FAs on mental health 
outcomes, research has begun to examine the underlying mechanisms that may explain this 
relationship (Polokowski, Shakil, Carmichael, & Reigada, 2018). Much of the research 
conducted to date involve animal subjects with a great amount of heterogeneity in results. Two 
potential mediators based on the literature explaining the relationship between ω-3 FAs and 
mental health symptoms are the inflammatory response and gut bacteria (Kaplan, Rucklidge, 
Romijn, & McLeod, 2015). Specifically, it has been hypothesized that a poor-quality diet may 
promote alteration in the gut microbiome, leading to an immune response of increased levels of 
inflammatory markers, subsequently leading to depression (Berk et al., 2013). We contributed to 
this innovative and burgeoning field of research by examining the relationship between nutrition 
(along with its potential biological effect on gut bacteria and inflammation) with mental health 
outcomes.  
This study examined the effect of ω-3 FAs directly and indirectly on mental health 
symptoms. The current study aimed to gain a better understanding of the ways in which ω-3 FAs, 





among a sample of healthy human subjects. We hypothesized a full mediation model such that 
ω-3 FAs influence the gut microbiome by increasing healthy gut bacteria and consequently 
reducing inflammation, resulting in decreased stress, anxiety, and depressive symptoms.  
The first aim of this study was to examine the cross-sectional relationships between ω-3 
FAs, gut microbiome bacteria, inflammation, and stress, anxiety and depressive symptoms. 
Several significant correlations were detected across variables and are discussed below. The 
second aim of the study was to examine whether specific gut bacteria and inflammatory markers 
mediate the relationship between ω-3 intake and psychological outcomes. Given there are four 
outcome variables (stress, trait-anxiety, state-anxiety, depression), four predictor variables (ω-3 
Index, DHA, EPA, ALA), and six mediator variables (Lactobacillus, Bifidobacterium, and TNF-
α, IL-6, IL-8, IL-1β), 128 mediation analyses were conducted. Overall, across all serial 
mediation models, no mediation was detected. Thus, we did not find gut bacteria or 
inflammation to mediate the relationship between ω-3 FAs and stress, anxiety, or depression 
symptoms. However, several significant direct effects were noted within the models and are 
described below.  
Omega-3 FAs and Mental Health Outcomes  
One key finding from the present study is that ω-3 index and DHA were negatively 
associated with trait-anxiety and depressive symptoms. That is, for participants with greater 
amounts of ω-3 index or DHA, fewer depression and trait-anxiety symptoms were reported. 
Direct effects among these variables were also replicated in the mediation analyses. Our findings 
partially support our hypothesis that there would be a negative relationship between ω-3 FAs and 
stress, anxiety, and depressive symptoms. No relationships were noted between EPA or ALA and 





It is well established in the literature that higher levels of ω-3 FAs are associated with 
less depressive symptoms (Golding et al., 2009; Raeder et al., 2007) and more recently research 
has reported a similar association with anxiety disorders (Jacka et al., 2013), and comorbid 
depression and anxiety disorders (Thesing, Bot, Milaneschi, Giltay, & Penninx, 2017). 
Additional, support for the link between ω-3 FAs and mental health has also been tested using 
RCT designs. One RCT with 432 adult outpatients experiencing a major depressive episode 
demonstrated that participants taking ω-3 FAs showed reduced depressive symptoms as 
compared to those taking a placebo (Lesperance, 2011). Another RCT examining children with 
major depressive disorder who were administered a ω-3 supplement or placebo (Nemets, Apter, 
Bracha, & Belmaker 2006) found that ω-3 supplement demonstrated therapeutic benefits in 
depression based on both clinician and patient report. Furthermore, a RCT examining substance 
users found that ω-3 supplementation improved anxiety symptoms compared to those in a 
placebo condition (Buydens-Branchey, Branchey, & Hibbeln, 2008). Similarly, a systematic 
review and meta-analysis of ω-3 FAs and anxiety found much heterogeneity, yet an overall 
reduction in anxiety symptoms with those participants receiving ω-3 FA supplements compared 
to controls (Su, et al., 2018). The findings of this study further contribute to this growing body of 
research, supporting a negative association between ω-3 FAs and depression and anxiety 
symptoms.  
While this study did find that ω-3 index and DHA levels were associated with fewer 
depression and trait-anxiety symptoms, no relationship was noted with the other psychological 
outcomes (state-anxiety or stress symptoms). Trait-anxiety and depression symptoms assessed in 
this study likely reflect a more stable, prominent, and consistent pattern of mood in participants 





highly comorbid with anxiety disorders (Richter et al., 1998) which may explain the similar 
findings in trait-anxiety and depression symptoms. In comparison, state-anxiety can be described 
as an anxiety response to a specific stressor where a circumstance is perceived as threatening 
(Barnes, Harp, & Jung, 2002). Similar to state-anxiety, the PSS assessed stress symptoms over 
the past month (Cohen, Kamarck, & Mermelstein, 1994). The PSS and state-anxiety likely 
overlap as they are designed to assess perceived feelings of stress or anxiety in a more fluid 
context.  
Others have also noted that more persistent and stable psychological symptoms are 
related to diet compared to more temporary states of anxiety or stress (Grosso et al. 2014a). The 
review paper conducted by Su and colleagues (2018) examining anxiety symptoms after ω-3 FA 
supplementation, supports our study findings as they note that subgroups with a clinical 
diagnosis, compared to those without, demonstrated a greater reduction in anxiety symptoms. 
Accordingly, diet may be a more beneficial intervention for populations with clinical symptoms 
rather than general populations. Clinical trials have shown that individuals with clinical 
diagnoses of major depressive disorder, anxiety, and early phase psychosis have benefitted from 
ω-3 FA supplementation (Chen, Chibnall, & Nasrallah, 2015; Grosso et al. 2014a; Su et al., 
2018). In a cohort of French adults followed for two years, subjects whom consumed fatty fish or 
whom had an intake of ω-3 FA higher than 0.10% of energy intake demonstrated less risk of a 
depressive episode and of a recurrent depressive episode (Astorg, et al., 2008). These findings 
suggest that it may be more valuable to conduct future investigations of ω-3 FA supplementation 
with samples with more chronic symptomatology compared to individuals with sub-clinical 





 In addition, the current study found that the type of ω-3 FA mattered. Results showed 
that DHA predicted less depression and trait-anxiety symptoms while EPA and ALA were not 
associated psychological outcomes. There has been some evidence supporting the negative 
relationship between DHA and depression symptoms in healthy adults (Mamalakis, Tornaritis, & 
Kafatos, 2002; Sarri, Linardakis, Tzanakis, & Kafatos, 2008). Specifically, it has been shown 
that higher DHA levels in mothers’ breast milk predicted lower rates of postpartum depression 
(Hibbeln, 2002). In a postmortem study, patients with major depressive disorder had 
significantly less DHA in the orbitofrontal cortex compared to controls (McNamara et al., 2007). 
Furthermore, one case control study investigating 800 United States military personnel compared 
to 800 controls, found that low levels of DHA was a significant risk factor for suicide, while 
there was no association with EPA levels (Lewis et al., 2011). These findings highlight the value 
of DHA. In particular, incorporating DHA via supplements or dietary sources may be a novel yet 
significant intervention when treating individuals with severe psychological symptoms such as 
major depression or suicidality.   
One area that requires further examination is why our findings only showed an 
association between DHA and depression and trait-anxiety symptoms, but not other types of ω-3 
FA. Both DHA and EPA are found within the same food groups such as fish, shellfish, and algae 
(Anderson & Ma, 2009) which indicates that differences in dietary sources of our participants are 
an unlikely explanation. One possible explanation for the difference in ω-3 FA type and 
psychological outcomes is that the process by which DHA and EPA metabolizes may be distinct 
from one another. Indeed, researchers have not clearly identified the ways in which DHA is 
metabolized. Across the literature, the majority of studies report DHA levels within the blood, 





brain (Sublette, Ellis, Geant, & Mann, 2011). There seems to be varying mechanisms by which 
DHA is transported to the brain and to the blood based on animal models which remain to be 
unclear (Chouinard-Watkins, Lacombe, Metherel, Masoodi, & Bazinet, 2019). Furthermore, it 
has been established that there is greater abundance of DHA in the brain compared to EPA, 
however, it is unclear whether EPA metabolizes more quickly than DHA or if there is low EPA 
uptake by the brain (Sublette, Ellis, Geant, & Mann, 2011; Hallahan et al., 2016). Research has 
also demonstrated that DHA clears from plasma at a slower rate than EPA, with some evidence 
showing that after 24 weeks of discontinuing ω-3 supplements, DHA levels did not reach 
baseline levels (Arterburn, Hall, & Oken, 2006). Thus, DHA may be detected in red blood cells 
for longer periods of time than EPA. In regards to the present study, we found support for DHA, 
and not EPA, predicting less depression and trait-anxiety symptoms based on levels within whole 
blood samples. This finding further supports the growing acknowledgement that there are 
differences between EPA and DHA. When evaluating the literature examining EPA and DHA, it 
is important to evaluate RCT’s and cross-sectional research independently. For instance, much of 
the research trials administering EPA and DHA supplements to participants do not objectively 
assess EPA and DHA in participants (Hallahan et al., 2016) and many of the cross-sectional 
studies do not assess EPA and DHA intake via diet or supplements.  
Given that the present study examines cross-sectional data, it is necessary to consider that 
individuals with less anxiety and depression may make healthier food choices that results in 
higher ω-3 FA intake rather than their diet affecting their mental health. For instance, 
undergraduate students who reported increased stress while waiting for an exam grade 
experienced increased tendency to eat compared to a control group (Macht, Haupt, & Ellgring, 





food compared to women in a low-stress condition (Habhab, Sheldon, & Loeb, 2008). Research 
has also shown that foods higher in fat may reduce stress (Finger, Dinan, & Cryan, 2011; 
Maniam & Morris, 2010). Careful consideration must be made when evaluating the relationship 
between diet and mental health. There is likely a bidirectional relationship between affect and 
food choice in which psychological state influence food choice and food consumed can influence 
affect (Gibson, 2006). 
Omega-3 FAs and Inflammation 
 Contrary to much of the literature and our hypothesis, lower ω-3 FA intake was not 
associated with lower inflammatory markers. In general, there was no relationship between ω-3 
FAs and inflammatory markers, with one exception, higher levels of EPA significantly predicted 
greater levels of inflammatory marker IL-6. Some clinical trials administering ω-3 supplements 
in medical populations (e.g., hypertriglyceridemia, obesity) have not found an effect of ω-3 FAs 
on inflammation, which may be due to treatment duration or negative impacts on insulin 
sensitivity which can increase inflammatory markers (Chan, Watts, Barrett, Beilin, & Mori, 
2002; Skulas-Ray et al., 2011). However, our findings were unexpected given that ω-3 FA 
supplementation has been widely shown to reduce inflammatory markers (Li, Huang, Zheng, 
Wu, & Li, 2014; Wall, Ross, Fitzgerald, & Stanton, 2010). One study examining the impact of 
EPA and DHA on inflammatory markers in adipocytes (cells storing fat) has shown that EPA 
supplementation increased the concentration of IL-6 while DHA decreased the concentration of 
IL-6 (Prostek, Gajewska, Kamola, & Balaninska, 2014). The authors posit that EPA and DHA 
may have a different effect on the inflammatory process during various stages of cell maturation 
which may explain why EPA has shown to potentially both reduce (Hao et al., 2010) and 





inflammatory properties, a couple of review articles (Hawkley, Bosch, Engeland, Cacioppo, & 
Marucha, 2007; Woods, Vieira, & Keylock, 2009) note the anti-inflammatory nature of IL-6 
which may be one possible explanation as to why EPA may be related to increased IL-6. It has 
been found that IL-6 may inhibit the response of increased levels of IL-1β and TNF-α and play a 
role in impeding the inflammatory response (Luheshi et al., 1997).  
It is important to acknowledge that the method of inflammatory marker assessment was 
via saliva. Salivary inflammatory markers have been shown to be sensitive to acute stress, even 
collecting salivary samples at multiple time points at one laboratory visit can demonstrate 
differences in levels of inflammation (Slavish, Graham-Engeland, Smyth, & Engeland, 2015). In 
the present study, we attempted to control for experimental stress effects on inflammation by 
collecting the saliva sample at the beginning of the lab visit; prior to the finger prick and the 
administration of self-report measures to reduce the potential contribution of acute stress in 
salivary measurement. Additionally, we also attempted to control for confounding inflammation 
factors by excluding participants from our study who were diagnosed with an inflammatory or 
endocrine illness, engaged in heavy alcohol use (more than two glasses of alcohol per day) or 
heavy smoking (more than eight cigarettes per day). However, we did not control for the 
waketime of participants. It has been shown that inflammatory markers may vary in salivary 
samples based on time of the day a sample is provided (DeSantis et al., 2013). Lastly, oral health 
status (e.g., gingivitis) may confound measures of salivary inflammation (Deinzer et al., 2004) 
which was not assessed in our sample. 
Inflammation and Mental Health Outcomes  
 We hypothesized that higher levels of inflammation would be associated with more 





relationship noted between inflammatory marker IL-1β and depression symptoms, and higher 
levels of IL-1β and IL-6 significantly predict higher levels of stress symptoms. These findings 
are consistent with a vast majority of the literature supporting the positive association between 
inflammation and anxiety and depression (da Silva et al., 2017; Das, 2016; Dowlati et al., 2010; 
Howren, Lamkin, Suls, 2009).  
These findings add to the robust literature that inflammation is a critical component of 
psychological health and should be targeted while treating patients with psychiatric illnesses. A 
meta-analysis examining 14 RCTs with over 6,000 patients concluded that anti-inflammatory 
treatment, specifically, nonsteroidal anti-inflammatory drugs, reduced depression symptoms and 
did not increase patient’s risk for adverse events (Köhler, et al., 2014). Furthermore, there is 
much evidence supporting that stress activates an inflammatory response via the hypothalamic-
pituitary-adrenal (HPA) axis which increases the expression of pro-inflammatory cytokines (Liu, 
Wang, & Jiang, 2017). There is considerable evidence for the bidirectional relationship between 
inflammation and depression, however it is likely that inflammation does not play a role in all 
individuals with depression. Keicolt-Glaser and colleagues (2015) discuss the ways in which 
multiple factors may contribute to a more robust inflammatory response (e.g., childhood 
adversity, obesity, poor diet) in some individuals with depression and that targeting inflammation 
in this population is essential for successful treatment.  
Gut Bacteria and Inflammation  
Although not hypothesized a priori, there was a small positive association between 
Lactobacillus and IL-8 in that increased levels of Lactobacillus significantly predicted higher 
levels of IL-8. This finding was unanticipated as Lactobacillus and Bifidobacterium were 





inflammation, this would be an important finding to replicate given that this is classified as a 
healthy bacteria and incorporated within many probiotic supplements. Similar to the present 
finding, one study unexpectedly found that a high dose probiotic, including Lactobacillus did 
increase IL-8 production (Zhang, Li, Caicedo, & Neu, 2005). The authors posit that the 
overgrowth of some bacteria may potentially stimulate the inflammatory response. Thus, it is 
possible that our sample had high levels of Lactobacillus which may have increased IL-8 
production.     
The research is novel when examining the relationship between gut bacteria and 
inflammatory markers, with much of the studies conducted in animal models. A study examining 
the effect of Lactobacillus in arthritic rats found that the rats that orally consumed Lactobacillus 
experienced less joint inflammation than those rats who did not consume Lactobacillus (Baharav, 
Mor, Halpern, & Weinberger, 2004). One study conducted in human subjects found that bacteria 
Faecalibacterium prausnitzii, has been shown to demonstrate anti-inflammatory effects in 
patients with Crohn’s disease, specifically blocking IL-8 production (Sokol et al., 2008). 
Schirmer and colleagues (2016) have developed a database of predicted relationships between 
gut bacteria and cytokine responses based on 500 healthy individuals. They note a negative 
association between gut bacteria, Bifidobacterium adolescentis and TNF-α production. Due to 
the inherent difficulty of studying the gut microbiome (e.g., multiple confounding variables), 
clear relationships between gut bacteria and inflammatory markers are challenging to assess. As 
research continues to develop and the techniques become more advanced, investigators will be 







Strengths and Limitations   
The present study is novel in that it is the first to study the associations between ω-3 
intake, gut bacteria, inflammatory markers, and anxiety and depression outcomes in a human 
sample. We found evidence that higher levels of ω-3 index and DHA were associated with lower 
reported trait-anxiety symptoms, depressive symptoms, and lower concentrations of the 
inflammatory marker IL-1β. We aimed to understand the ways in which ω-3 FAs impact mental 
health outcomes by examining potential mediators. While gut bacteria and inflammation were 
not found to mediate the relationship between ω-3 and psychological outcomes, this study can be 
utilized as a framework and set the foundation for future research to examine these variables. 
It has been recognized that one major source of heterogeneity in ω-3 FA research is the 
influence of sex (Martins, 2009). In addition, many studies do not report the breakdown of 
participant sex which is problematic. One strength of the current study is that, our sample was 
comprised of all female participants. Overall, females have been found to have higher levels of 
DHA compared to males, with the role of estrogen as one explanation (Kitson, Stroud, & Stark, 
2010). Estrogen has been shown to cause higher concentrations of DHA in women than in men 
(Giltay, Gooren, Toorians, Katan, & Zock, 2004). Kitson and colleagues (2010) posit that the 
difference in DHA levels between males and females may be evolutionary; females have higher 
concentrations of DHA in order to provide adequate DHA for fetal development. Thus, 
examining the impact of ω-3 supplementation in men and women separately may help explain 
some of the variance in findings.  
Another strength of the current study was the utilization of dried blood spot samples to 
assess ω-3 levels in our participants. This allows for an objective measure of ω-3 FAs rather than 





questionnaires. Based on our procedures of measuring ω-3 index via dried blood spots, we 
obtained fatty acid values from the whole blood fatty acid profile, meaning both red blood cells 
and plasma are collected by a finger prick. This method of assessing fatty acids via whole blood 
spot collection has been found to be reliable, non-invasive, and more economical compared to 
methods that require centrifugation (Gordon Bell et al., 2011). One study utilizing whole blood 
fatty acid demonstrated increases in EPA and DHA levels six weeks after a dietary intervention 
(Rise, Colombo, Ghezzi, Mauro, & Orlandini, 2011). Furthermore, four weeks post-intervention, 
DHA levels continues to increase and EPA levels decreased slightly. These findings support the 
utilization of whole blood fatty acid profiles as a method to assess ω-3 FA levels. 
One strength, and also a potential study limitation, is the ethnic diversity of the sample. 
The study was conducted in a metropolitan city in an urban university setting with a diverse 
sample of approximately 25% Black, 25% White, 25% Hispanic/Latino, 15% Asian, and the 
remaining participants identified as Mixed or Other. It is important to examine this demographic 
feature when studying ω-3 FAs given that ethnicity does seem to impact accessibility to ω-3 FAs 
or may influence genetic processing of ω-3 FAs. Certain cultures are exposed to higher 
concentrations of ω-3 FAs such as Inuit/Eskimo and Japanese populations (Patel, Tracey, 
Hughes, & Lip, 2010). Furthermore, some Europeans such as Italians tend to more efficiently 
incorporate ω-3 FAs into their diet (Patel, Tracey, Hughes, & Lip, 2010). As described in our 
results, Asian and Black participants were found to have higher levels of ω-3 index and DHA 
than other races, however this was anticipated based on the literature (Villegas, Takata, Murff, & 
Blot, 2016; Xiao et al., 2016).    
A main limitation of this study is the methodological use of cross-sectional data which 





of the relationships analyzed. Based on the current state of the research, we hypothesized that ω-
3 FAs will influence the gut microbiome by increasing healthy gut bacteria and subsequently 
reducing inflammatory cytokines, leading to decreased anxiety and depressive symptoms. 
However, this hypothesized theoretical framework may not be accurate. One alternative 
possibility is that anxiety and depressive symptoms may be increasing inflammation, leading to 
reductions in healthy gut bacteria with ω-3 FAs moderating this relationship. For instance, 
individuals with anxiety or depressive symptoms may demonstrate higher levels of inflammatory 
markers and lower levels of healthy gut bacteria, however, consuming higher amounts of ω-3 
FAs may serve as a protective factor against these negative effects.  
Furthermore, the examination of ω-3 FAs alone may be limited. Researchers have posited 
that it is important to examine both ω-3 and ω-6 FAs, as together they play a role in 
inflammatory responses in the human body (Wall, Ross, Fitzgerald, & Stanton, 2010). However, 
there is controversy within the literature regarding the utilization of the ω-6/ ω-3 ratio. Much 
research has been done surrounding ω-3 FA and their anti-inflammatory properties however the 
impact of ω-6 FAs is not as straightforward. Some ω-6 FAs have anti-inflammatory properties 
(e.g.,dihomo-γ-linolenic acid)  while others promote inflammation (e.g., arachidonic acid) 
(Harris et al., 2009; Poorani, Bhatt, Dwarakanath, & Das, 2015). Over the past century, there has 
been a drastic shift in dietary patterns, with a substantial increase in the amount of ω-6 FAs 
consumed, due to the large amount of LA-enriched vegetable oils in the food supply, and 
subsequently a deficiency of ω-3 FAs in the Western diet (Simopoulos, 2002). Some researchers 
support the belief that this imbalance has resulted in a high ω-6 to ω-3 ratio of approximately 





the ideal ratio of ω-6 to ω-3 is 4:1 or 1:1 (Simopoulos, 2008). However, others claim that there is 
no evidence that reducing ω-6 FA intake will prevent chronic illness (Harris, 2006).  
Another weakness to this study lies within preliminary assessment and examination of 
gut microbiome data in human subjects. There is more to be learned in the sampling and 
processing of stool samples and recent research is attempting to create guidelines for collecting 
stool samples to improve the validity of gut microbiome results (Gorzelak et al., 2015). There is 
a limited understanding of the ways in which to interpret the gut microbiome as there are 
countless numbers of microorganisms in the gastrointestinal tract. It is difficult to parse out the 
specific impact of a particular bacteria given the all the factors that influence the microbiome. 
Various environmental factors can influence the gut microbiome including antibiotics, diet, clean 
environments, and stress (Kaplan, Rucklidge, Romijn, & McLeod, 2015). Some literature has 
supported the idea that more diversity in the microbiome is healthier and having a less diverse 
microbiome may be associated with chronic medical conditions (Liu, 2017). Thus, the gut 
bacteria findings in the present study are preliminary and must be interpreted with caution.  
A methodological limitation of the present study was the adherence of participants to 
complete the uBiome gut kits. Participants completed majority of the study assessments in the 
research lab, however, they subsequently were asked to submit a stool sample using the uBiome 
kit after the lab visit. Of the 79 total participants, 67 completed and mailed in the uBiome kit 
which is an 84.8% adherence rate. This resulted in missing gut bacteria data for a portion of our 
sample. On average, our participants mailed out the uBiome kits within 4 days of receiving the 
kit and completing baseline measures. In an attempt to increase adherence rates, research 
assistants sent an email to participants the day after their assessment to verify their status on 





is unclear whether the participants correctly adhered to the instructions given to complete the 
stool sample kit. There is little research published on adherence rates of gut bacteria kits 
provided to study participants in a lab setting as this is a novel assessment in human participants. 
To date, studies have collected fecal samples on human subjects via a research nurse collecting 
directly from an adult participant’s home (Hill et al., 2016) or have been collected in infant 
samples while they are admitted to the hospital (Williams et al., 2019). There has been some 
research on adherence rates for self-collection methods in the cancer screening literature. When 
offered to self-screen for cervical cancer at home with a kit, response rates were approximately 
20-25% for women who received a kit in the mail (Gupta et al., 2018). Additional research is 
needed surrounding adherence rates for self-collection procedures of stool samples by 
participants outside of laboratory settings.  
Another limitation was that our data did not meet the assumptions for normality. Due to 
the non-normality of the data, Spearman’s correlation was utilized for the first aim of the study. 
Spearman’s correlation is recommended when analyzing non-normal distributions while 
maintaining Type 1 error rates (Bishara & Hittner, 2012). Additionally, as with any research 
study using self-report data, there is a risk for biased responses. We administered self-report 
measures of stress, anxiety, and depression symptoms. It is possible that participants were 
inclined to respond to measures in a socially desirable manner (van de Mortel, 2008) and 
conducting a structured interview to assess psychological symptoms could have potentially 
improved the accuracy of mental health symptoms reported.  
Future Directions 
Based on the synthesis of the current research, a recommended next step would be to 





subthreshold and clinical levels of depression and anxiety. Prospective longitudinal studies such 
as these will produce findings that can clearly be interpreted as causal, and will reveal the 
magnitude of the specific types of ω-3 FAs on different types of symptomatology. Incorporating 
repeated measures in clinical trials are a critical component to assess changes over time. 
Moreover, prospective studies with a larger sample can test whether additional endogenous 
variables moderate the relationship between ω-3 intake and psychological symptoms such as 
race, gender, and biological markers (e.g., inflammatory markers, hormones). Future studies can 
also improve the assessment of inflammation in particular by utilizing blood samples over saliva. 
Measuring inflammatory markers via saliva has some benefits such as being non-invasive and 
minimizing participant burden, however, there are methodological downfalls such as 
inconsistency in collection methods and large variability in cortisol concentrations (Desai & 
Mathews, 2014).  
As mentioned in the Introduction, there are no established guidelines of ω-3 dosages to 
improve mental health symptoms. Across studies, there is a large amount of variability in the 
measurement and administration of ω-3 FAs. These methodological flaws seem to have an 
impact on the results reported in the literature. For instance, a meta-analysis assessing the effects 
of ω-3 FAs on major depressive disorder deemed the studies to be poor quality (e.g., non-
blinding of participants to ω-3 supplement conditions, small sample sizes) and noted that there 
was a large amount of heterogeneity among the studies reviewed (Appleton, Sallis, Perry, Ness, 
& Churchill, 2015). Additionally, there is a large variety in the dosage, purity, and type of ω-3 
FA supplements administered in clinical trials. As such, while conducting their meta-analysis, 
Grosso and colleagues (2014) created categories of the purity of supplements (e.g., mainly EPA, 





weeks to 160 weeks. In addition, each type of ω-3 (DHA, EPA, ALA) has shown to demonstrate 
differing effects on biological processes (Dyall, 2015), supporting the notion that standardization 
of ω-3 supplements administered in research trials is essential. The inconsistency across methods 
is a critical weakness within the literature, thus, it is challenging to evaluate the literature and to 
infer any robust conclusions between ω-3 FA and mental health outcomes. Thus, it is necessary 
for researchers to develop standard recommendations across ω-3 types, dosages, and durations 
within clinical trials in order to productively move forward in this field of research. 
There is continually a demand to improve assessment methods when conducting research, 
particularly within nutrition research. Many researchers utilize food frequency questionnaires, 
food diaries, and 24-hour recall methods to assess diet. Dietary self-report measures have 
consistently shown to result in underreporting of energy intake (Freedman et al., 2014) and are 
inaccurate due to poor evaluation of portion size or have an incomplete list of foods (Thompson 
& Subar, 2017). Incorporating the use of objective assessment measures such as blood samples 
(Johnston, Deuster, Harris, Macrae, & Dretsch, 2013) can improve accuracy in nutritional 
assessments and avoid participant biases in diet recall methods. Additionally, it would be 
beneficial for researchers to objectively assess both ω-6 and ω-3 FA levels. As mentioned earlier, 
there is controversy regarding the significance of the ω-6 to ω-3 ratio, however many studies 
only assess ω-3 FA levels. Including the assessment of various ω-6 FAs would increase our 
understanding of the role of ω-6 FAs on physical and mental health outcomes.  
Examining ethnicity more rigorously within ω-3 research is necessary given the clear 
baseline differences in ω-3 levels across races. Our study found higher levels of ω-3 levels in 
participants that identified as Asian/Pacific Islander and Black, compared to White and Hispanic 





Blot, 2016; Xiao et al., 2016). It is also been noted that individuals of Japanese descent have 
much higher concentrations of ω-3 levels compared to Americans (Iso et al., 1989). It is 
important for researchers to gather an accurate assessment of racial/cultural background, dietary 
history, and regional location of their participants prior to enrollment in a clinical trial in order to 
stratify their sample appropriately. This will increase the likelihood of well-defined results and a 
clearer understanding of the implications of ω-3 supplementation. Furthermore, given the 
differences in ω-3 levels across racial backgrounds, there are likely varying needs for different 
races. For instance, one review of nearly 300 studies evaluated EPA and DHA levels across 
countries globally (Stark, Van Elswyk, Higgins, Weatherford, & Salem, 2016). The authors 
identified a large amount of variability in ω-3 levels across regions, with those in the very low 
range potentially having an increased risk of chronic illness. Thus, ω-3 recommendations may 
not be consistent across racial groups and those with lower levels ω-3 will likely require higher 
ω-3 dosages.  
Based on our current findings, a next phase of research would be to develop an RCT 
investigating the impact of different types of ω-3 supplementation, such as, EPA versus DHA 
predominant formulas, across individuals with varying degrees of clinical symptoms, such as, 
subthreshold versus clinical levels of depression and anxiety. Utilizing diagnostic clinical 
interviews to evaluate the severity of psychological symptoms would be ideal. It would be 
important to stratify the sample by racial background due to variances across ω-3 FA levels. 
Another option would be to create a less ethnically diverse sample to help remove any 
confounding racial effects. Moreover, with the RCT, it will be necessary to utilize objective 
measures of ω-3 assessment (e.g., blood samples) to eliminate the potential of underreporting via 





assessment, post-assessment, follow-up) would also shed light on the ways in which ω-3 FAs 
metabolize and how long ω-3 FAs remain within the human body.  
Additional work needs to be done within psychological nutrition research to improve the 
standardization across trials. Specific recommendations have been suggested including 
developing consistency across the dosage and duration of ω-3 supplements administered, 
improving the measurement of diet and psychological symptoms, increasing diversity within 
samples, and designing clinical trials that test mediation (Polokowski, Shakil, Carmichael, & 
Reigada, 2018). These are some strategies to gain better insight into the ways in which ω-3 FAs 
may be related to psychological symptoms.     
Clinical Implications  
As rates of mental health disorders increase, it is necessary to evaluate lifestyle factors 
that may impact these disorders, as these factors have been overlooked in psychological 
intervention research. Nutrition has been identified as one avenue of research that relates to 
multiple biological mechanisms which may in turn influence anxiety and depression. 
Implementing dietary assessment and interventions into evidence-based practices can be cost-
effective and more easily tolerated than psychotropic medications (Freeman et al., 2006; 
Mozaffarian & Rimm, 2006). With increased attention focused on the connection between 
nutrition and mental health, there is promising research supporting the importance of diet as a 
favorable therapeutic option for managing psychological well-being. 
Assessing Diet in Clinical Practice 
Although nutritional status has been identified as an important component to mental 
health, clinicians are not provided standardized training to assess diet in their patients and 





Terry & Reeves, 2015). The biopsychosocial framework is a valuable model when intervening 
with diet because it considers the biological, social, psychological, and environmental factors 
associated with health behaviors (Suls & Rothman, 2004). Furthermore, with the expansion of 
multidisciplinary teams, clinicians will have increased access to dieticians or nutritionists to 
consult with or make referrals when they need additional support surrounding patients’ dietary 
issues.  
There are multiple ways to evaluate diet in the context of mental health care including 
assessing food selection, supplementation, or deficiencies (Walsh, 2011). Conducting a basic 
assessment of a patient’s diet may help guide treatment recommendations. For instance, caffeine 
has shown to increase anxiety and psychotic symptoms and impact sleep, thus a simple 
assessment of caffeine intake is recommended as part of any psychiatric assessment (Winston, 
Hardwick, Jaberi, 2005). It is also suggested that clinicians inquire about nutritional 
supplements, as many patients assume they are harmless, yet they have the potential to 
negatively interact with pharmaceutical drugs (Singh, 2005). With a brief assessment of diet, 
mental health professionals have the opportunity to discover key features of their patients which 
may influence treatment recommendations.  
Incorporating Dietary Interventions into Clinical Practice  
Dietary and nutritional supplements have been explored in relation to psychological 
health. For instance, a review article reported that low levels of folate (a B-vitamin) and vitamin 
B-12, have been found in samples of depressed patients (Coppen & Bolander-Gouaille, 2005). 
Furthermore, depressed patients responded better to antidepressant medication when folate and 
vitamin B-12 levels were higher (Coppen & Bolander-Gouaille, 2005; Miller, 2008). A recent 





concluded that overall results are inconclusive due to mixed results across studies, however there 
is some support for the supplementation of zinc and ω-3 FAs (Schefft, Kilarski, Bschor, Kohler, 
2017). Thus, some of the literature supports the notion that adding supplements to established 
therapeutic practices may increase efficacy, with ω-3 FAs in particular showing benefit (Dome, 
Tombor, Lazary, Gonda, & Rihmer, 2019).  
There is evidence that consuming ω-3 FAs via diet (e.g., salmon, enriched yogurt) 
demonstrate increased levels of plasma EPA and DHA (Elvevoll et al., 2006; Rise, Colombo, 
Ghezzi, Mauro, & Orlandini, 2011) compared to taking an ω-3 FA supplement (Ratnayake & 
Galli, 2009). Additionally, there is some evidence that consuming an ω-3 FA supplement with a 
meal high in fat may improve absorption of fatty acids (Opperman, 2013). Accordingly, if it is 
feasible for patients, it is recommended to consume ω-3 FAs via dietary intake as it seems this 
method has more advantageous effects compared to supplementation alone. Based on our 
findings, DHA in particular seemed to be related to psychological outcomes. Thus, it is 
recommended that foods higher in DHA such as seafood be incorporated into a patient’s 
treatment plan may be a simple yet effective intervention. Additionally, based on the present 
study, it seems that practical applications should aim to target more severe clinical samples, as 
they demonstrate more benefit from ω-3 FA supplementation. 
Common Barriers in Dietary Interventions. 
It is known that individuals with higher rates of anxiety and depressive symptoms 
generally have poorer lifestyle behaviors (e.g., poorer diets) which may have influenced our 
findings (Parletta, Aljeesh, and Baune, 2016), for instance, they would be less likely to consume 
ω-3 FAs or diets that may increase healthy gut bacteria. In practice, there are multiple factors to 





economic status, nutritional education, living environments and cultural values. It has been found 
that individuals with a lower socioeconomic status are exposed to poorer quality food options 
which results in unhealth eating patterns (Ford & Dzewaltowski, 2008). Additionally, individuals 
are consuming more calories than ever before due to our culture being flooded by fast food 
restaurants, larger portion sizes, and an increase in energy dense foods, all for a low cost 
(Drewnowski & Darmon, 2005). Results from a meta-analysis show that on average, eating a 
healthier diet, such as fruits, vegetables, fish, and nuts, is more expensive than consuming a less 
healthy diet consisting of meats and refined grains (Rao, Afshin, Singh, & Mozaffarian, 2013). 
Many patients may not have the means or accessibility to access certain food options. Thus, 
clinicians may face larger challenges when attempting to provide dietary recommendations and 
must consider social and environmental factors.  
Although significant work is still needed, developing clinical interventions that 
incorporate a dietary component may be a noteworthy next step in treating psychological 
conditions.  
Conclusion 
As there are drastic shifts in diets across the globe, the literature continues to identify 
trends in how diet is associated with mental health outcomes. Specifically, ω-3 FAs possess 
numerous physical and mental health benefits and are acknowledged as a necessary component 
of a healthy lifestyle. Recently, there has been an increase in research investigating potential 
biological mechanisms that may clarify the ways in which ω-3 FAs may prevent or treat mental 
health symptoms. Furthermore, growing evidence suggests that the gut microbiome promotes or 
prevents inflammatory responses which in turn may lead to neuropsychiatric disorders. The 





gaining a greater understanding of the impact on inflammation, gut bacteria, and mental health 
outcomes.  
Main findings from the current study demonstrated that higher levels of ω-3 index and 
DHA significantly predicted fewer trait-anxiety and fewer depressive symptoms suggesting that 
ω-3 supplementation may demonstrate benefit over mental health symptoms. Moreover, higher 
levels of inflammatory markers IL-1β and IL-6 were shown to significantly predict higher levels 
of stress symptoms, while higher levels of EPA significantly predicted higher levels of IL-6. 
Lastly, greater abundance of gut bacteria Lactobacillus significantly predicted higher levels of 
IL-8. We are in the preliminary stages of understanding the ways in which specific nutritional 
components such as ω-3 FAs, may have an impact on psychological health, yet researchers must 
improve the methodology examining these variables in order to develop meaningful conclusions. 
In order to utilize ω-3 FAs as therapeutic option for depression and anxiety, we must first 
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ALA: α -linolenic acid 
AA: Arachidonic acid  
BDI: Beck Depression Inventory 
CRP: C-reactive protein 
DHQ: Diet History Questionnaire  
DHA: Docosahexaenoic acid  
EFA: Essential Fatty Acid 
EPA: Eicosapentaenoic acid  
GIT: Gastrointestinal tract  
GAD: Generalized Anxiety Disorder  
ILD-6: Interleukin 6  
IL-8: Interleukin 8 
IL-1b. Interleukin 1 beta 
LA: Linoleic acid  
MDD: Major Depressive Disorder 
MeSH: Medical subject headings 
OCD: Obsessive-Compulsive Disorder  
ω-3 FAs: Omega-3 fatty acids  
ω-6 FAs: Omega-6 fatty acids 
PSS: Perceived Stress Scale  
TNF-α: Tumor necrosis factor alpha  
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Room 4611 or 





Meet with Principal Investigator (PI) or Research Personnel  
 
Complete multiple questionnaires: 
     1. Demographic Questionnaire (e.g., age, sex, ethnicity) 
     2. Diet History Questionnaire (DHQ): assesses regular eating habits 
     3. State-Trait Anxiety Inventory (STAI): evaluates anxiety 
symptoms 
     4. Beck Depression Inventory (BDI): evaluates depressive 
symptoms 
     5. Perceived Stress Scale (PSS): evaluates stress symptoms  
 
• Provide a saliva sample 
• Receive a stool sampling kit and directions on collecting stool 
samples and submitting kit to PI or mailing to external laboratory  
• Receive supply of omega-3 fatty acid pills, probiotic, or 
combination of both, and directions on taking the supplements 
• Receive directions on diet and lifestyle habits to avoid or to note 
during experiment 
• Receive directions on recording omega-3 and omega-6 content 
throughout the week 
Pre-test 
(Day 0) In private 
In private collect own stool sample and follow directions to submit to 





In private Take supplements daily as directed Record diet once per week 
Post-test 
(Week 13) REACH Lab 
Return to REACH Lab to meet with PI 
 
Complete multiple questionnaires: 
     1. Demographic Questionnaire 
     2. Diet History Questionnaire (DHQ) 
     3. State-Trait Anxiety Inventory (STAI) 
     4. Beck Depression Inventory (BDI) 






• Provide a saliva sample 
• Receive a stool sampling kit and directions on collecting stool 
samples and submitting kit to PI or mailing to external laboratory  
Post-test 
(Week 13) In private 
In private collect own stool sample and follow directions to submit to 
outside lab via mail, or return kit to research staff to submit via mail 
 Debriefin
g REACH Lab 
Return to REACH lab after providing stool sample to debrief on the 










you	would	 like	to	obtain	mental	health	services	 for	any	reason,	please	contact	 the	
Brooklyn	 College	 Personal	 Counseling	 Center	 in	 room	 0203	 in	 James	 Hall,	 2900	
Bedford	 Ave,	 Brooklyn,	 NY	 or	 call	 them	 at	 718-951-5363.	 Additionally,	 a	 Suicide	




• For	 stool	 sample:	 You	 may	 feel	 uncomfortable	 providing	 a	 stool	 sample.	 The	
researchers	have	provided	you	an	individual	kit	with	directions	which	you	can	use	to	
collect	your	stool	in	private.	You	have	the	option	of	mailing	out	your	sample	via	mail	
to	uBiome,	 the	stool	 testing	service,	yourself	or	can	give	your	 individual	kit	 to	 the	






















• This	 study	 will	 help	 you	 gain	 essential	 dietary	 nutrients	 recommended	 by	 the	
American	Heart	Association	and	the	Federal	Government.	 
o Studies	 suggest	 that	 consumption	 of	 omega-3	 fatty	 acids	 could	 improve	
cholesterol	profiles	of	people	by	increasing	HDL	and	decreasing	LDL	and	could	




could	 potentially	 lower	 cholesterol,	 hypertension,	 and	 postmenopausal	









































information	 will	 be	 kept	 separate	 from	 all	 other	 study	 data	 to	 ensure	 confidentiality.	
Additionally,	 all	questionnaires,	 saliva	 samples,	 computer	 tasks	and	worksheets	will	only	
include	your	participant	 ID	and	de-identified	paper	 forms	will	be	stored	 in	a	cabinet	 in	a	
locked	office.	The	list	with	identifying	information	will	be	destroyed	upon	completion	of	data	
collection.	Consent	 forms	with	names	will	be	stored	separately	 in	a	 locked	office,	will	not	
include	any	linking	information	(i.e.,	ID	number)	and	will	be	destroyed	after	3	years.	
	




Health	 Insurance	 Portability	 and	 Accountability	 Act	 of	 1996	 (HIPAA)	 to	 keep	 all	 health	
information	confidential.		
	



























Principal	 Investigator,	 Ashley	 Polokowski	 at	 718-951-5000	 ext.	 6651,	 or	 at	































Appendix B. Demographic Form 
Date (m/d/y):_________             ID#:___________ 
Baseline Demographic Information 
1. What is your age? _________ 
2. Please specify your gender. _____________ 
3. Please specify your ethnicity. 
  White 
  Hispanic or Latino 
  Black or African American 
  Native American or American Indian 
  Asian / Pacific Islander 
  Other ___________ 
4. What is the highest degree or level of school you have completed? If currently enrolled, 
highest degree received. 
  No schooling completed 
  Nursery school to 8th grade 
  Some high school, no diploma 
  High school graduate, diploma or the equivalent (for example: GED) 
  Some college credit, no degree 
  Trade/technical/vocational training 
  Associate degree 
  Bachelor’s degree 
  Master’s degree 
  Professional degree 
  Doctorate degree 
5. What is your marital status? 
  Single, never married 





6. Are you currently…? 
  Employed for wages 
  Self-employed 
  Out of work and looking for work 





  A homemaker 
  A student 
  Military 
  Retired 
  Unable to work 
 
6A. If you are working, how many hours a week do you work? ________ 
 
7. What was your total household income during the past 12 months? 
  Less than $25,000 
  $25,000 to $34,999 
  $35,000 to $49,999 
  $50,000 to $74,999 
  $75,000 to $99,999 
  $100,000 to $149,999 
  $150,000 or more 
 
8. If you were born in the United States, which region of the country were you born in? 
  New England - Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, 
Vermont 
  Middle Atlantic - New Jersey, New York, Pennsylvania 
  East North Central - Illinois, Indiana, Michigan, Ohio, Wisconsin 
  West North Central - Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota, South 
Dakota 
  South Atlantic - Delaware, District of Columbia, Florida, Georgia, Maryland, North 
Carolina, South Carolina, Virginia, West Virginia 
  East South Central - Alabama, Kentucky, Mississippi, Tennessee 
  West South Central - Arkansas, Louisiana, Oklahoma, Texas 
  Mountain - Arizona, Colorado, Idaho, Montana, Nevada, New Mexico, Utah, Wyoming 
  Pacific - Alaska, California, Hawaii, Oregon, Washington 
 
 
8A. How long did you live there? ____________________ 
 
 9. If you were not born in the United States, what country were you born in? 
____________________________________________________________________________ 
 9A. How long did you live there? ____________________ 
 
10. What neighborhood do you currently live in? __________________________________  
11. How many people currently live in your household? ____________________________ 

































Appendix C. Perceived Stress Scale  
PERCEIVED STRESS SCALE  
The questions in this scale ask you about your feelings and thoughts during the last month. In 
each case, you will be asked to indicate by circling how often you felt or thought a certain way.  
 
Name ____________________________________________________________  
Date ______________  
Age ________  
Gender (Circle): M F Other _____________________________________  
 
0 = Never 1 = Almost Never 2 = Sometimes 3 = Fairly Often 4 = Very Often  
1. In the last month, how often have you been 
upset because of something that happened 
unexpectedly?  
0  1  2  3  4  
2. In the last month, how often have you felt 
that you were unable to control the important 
things in your life?  
0  1  2  3  4  
3. In the last month, how often have you felt 
nervous and “stressed”?  
0  1  2  3  4  
4. In the last month, how often have you felt 
confident about your ability to handle your 
personal problems?  
0  1  2  3  4  
5. In the last month, how often have you felt 
that things were going your way?  
0  1  2  3  4  
6. In the last month, how often have you found 
that you could not cope with all the things that 
you had to do?  
0  1  2  3  4  
7. In the last month, how often have you been 
able to control irritations in your life?  
0  1  2  3  4  
8. In the last month, how often have you felt 
that you were on top of things?  
0  1  2  3  4  
9. In the last month, how often have you been 
angered because of things that were outside of 
your control?  
0  1  2  3  4  
10. In the last month, how often have you felt 
difficulties were piling up so high that you could 
not overcome them?  








Appendix D. State-Trait Anxiety Inventory  
SELF-EVALUATION QUESTIONNAIRE STAI Form Y-1 
 
Please provide the following information:  
Name _________________________________________ Date_____________  S ______ 
Age __________________  Gender   (Circle) M    F                                             T ______ 
 
DIRECTIONS: 
A number of statements which people have used to describe themselves are given below. Read 
each statement and then blacken the appropriate circle to the right of the statement to indicate 
how you feel right now, that is, at this moment. There are no right or wrong answers. Do not 
spend too much time on any one statement but give the answer which seems to describe your 
present feelings best. 
 
1 = Not At All 2 = Somewhat 3 = Moderately So 4 = Very Much So 
 
1. I feel calm.......................................................................................................................... 1 2 3 4 
2. I feel secure........................................................................................................................ 1 2 3 4 
3. I am tense .......................................................................................................................... 1 2 3 4 
4. I feel strained ..................................................................................................................... 1 2 3 4 
5. I feel at ease ...................................................................................................................... 1 2 3 4 
6. I feel upset.......................................................................................................................... 1 2 3 4 
7. I am presently worrying over possible misfortunes........................................................... 1 2 3 4 
8. I feel satisfied..................................................................................................................... 1 2 3 4 
9. I feel frightened.................................................................................................................. 1 2 3 4 
10. I feel comfortable............................................................................................................. 1 2 3 4 
11. I feel self-confident.......................................................................................................... 1 2 3 4 
12. I feel nervous ................................................................................................................... 1 2 3 4 
13. I am jittery........................................................................................................................ 1 2 3 4 
14. I feel indecisive................................................................................................................ 1 2 3 4 
15. I am relaxed...................................................................................................................... 1 2 3 4 
16. I feel content ................................................................................................................... 1 2 3 4 
17. I am worried..................................................................................................................... 1 2 3 4 
18. I feel confused.................................................................................................................. 1 2 3 4 
19. I feel steady...................................................................................................................... 1 2 3 4 














SELF-EVALUATION QUESTIONNAIRE STAI Form Y-2 
 
Name _________________________________________ Date_____________   
 
DIRECTIONS: 
A number of statements which people have used to describe themselves are given below. Read 
each statement and then blacken in the appropriate circle to the right of the statement to indicate 
you generally feel. 
 
1 = Almost Never = Sometimes 3 = Often 4 = Almost Always 
21. I feel pleasant................................................................................................................... 1 2 3 4 
22. I feel nervous and restless................................................................................................ 1 2 3 4 
23. I feel satisfied with myself............................................................................................... 1 2 3 4 
24. I wish I could be as happy as others seem to be ............................................................. 1 2 3 4 
25. I feel like a failure............................................................................................................ 1 2 3 4 
26. I feel rested....................................................................................................................... 1 2 3 4 
27. I am “calm, cool, and collected”...................................................................................... 1 2 3 4 
28. I feel that difficulties are piling up so that I cannot overcome them............................... 1 2 3 4 
29. I worry too much over something that really doesn’t matter........................................... 1 2 3 4 
30. I am happy........................................................................................................................ 1 2 3 4 
31. I have disturbing thoughts................................................................................................ 1 2 3 4 
32. I lack self-confidence....................................................................................................... 1 2 3 4 
33. I feel secure...................................................................................................................... 1 2 3 4 
34. I make decisions easily ................................................................................................... 1 2 3 4 
35. I feel inadequate............................................................................................................... 1 2 3 4 
36. I am content...................................................................................................................... 1 2 3 4 
37. Some unimportant thought runs through my mind and bothers me................................. 1 2 3 4 
38. I take disappointments so keenly that I can’t put them out of my mind ......................... 1 2 3 4 
39. I am a steady person......................................................................................................... 1 2 3 4 













Appendix E. Beck Depression Inventory  
 
 Beck's Depression Inventory  
This depression inventory can be self-scored. The scoring scale is at the end of the questionnaire.  
1.  
0 I do not feel sad.  
1 I feel sad  
2 I am sad all the time and I can't snap out of it.  
3 I am so sad and unhappy that I can't stand it.  
2.  
0 I am not particularly discouraged about the future.  
1 I feel discouraged about the future.  
2 I feel I have nothing to look forward to.  
3 I feel the future is hopeless and that things cannot improve.  
3.  
0 I do not feel like a failure.  
1 I feel I have failed more than the average person.  
2 As I look back on my life, all I can see is a lot of failures.  
3 I feel I am a complete failure as a person.  
 
4.  0 I get as much satisfaction out of things as I used to.  
1 I don't enjoy things the way I used to.  
2 I don't get real satisfaction out of anything anymore.  
3 I am dissatisfied or bored with everything.  
 
5.  0 I don't feel particularly guilty  
1 I feel guilty a good part of the time.  
2 2 I feel quite guilty most of the time.  
3 I feel guilty all of the time.  
 
6.  0 I don't feel I am being punished.  
1 I feel I may be punished.  
2 I expect to be punished.  
3 I feel I am being punished.  
 
7.  0 I don't feel disappointed in myself.  
1 I am disappointed in myself.  
2 I am disgusted with myself.  
3 I hate myself.  
 
8.  0 I don't feel I am any worse than anybody else.  
1 I am critical of myself for my weaknesses or mistakes.  
2 I blame myself all the time for my faults.  
3 I blame myself for everything bad that happens.  
 
9.  0 I don't have any thoughts of killing myself.  





2 I would like to kill myself.  
3 I would kill myself if I had the chance.  
 
10.  0 I don't cry any more than usual.  
1 I cry more now than I used to.  
2 I cry all the time now.  
3 I used to be able to cry, but now I can't cry even though I want to.  
 
11.  0 I am no more irritated by things than I ever was.  
1 I am slightly more irritated now than usual.  
2 I am quite annoyed or irritated a good deal of the time.  
3 I feel irritated all the time. 
 
12.  0 I have not lost interest in other people.  
1 I am less interested in other people than I used to be.  
2 I have lost most of my interest in other people.  
3 I have lost all of my interest in other people.  
 
13.  0 I make decisions about as well as I ever could.  
1 I put off making decisions more than I used to.  
2 I have greater difficulty in making decisions more than I used to.  
3 I can't make decisions at all anymore.  
 
14.  0 I don't feel that I look any worse than I used to.  
1 I am worried that I am looking old or unattractive.  
2 I feel there are permanent changes in my appearance that make me look unattractive  
3 I believe that I look ugly.  
 
15.  0 I can work about as well as before.  
1 It takes an extra effort to get started at doing something.  
2 I have to push myself very hard to do anything.  
3 I can't do any work at all.  
 
16.  0 I can sleep as well as usual.   
1 I don't sleep as well as I used to.  
2 I wake up 1-2 hours earlier than usual and find it hard to get back to sleep.  
3 I wake up several hours earlier than I used to and cannot get back to sleep.  
 
17.  0 I don't get more tired than usual.  
1 I get tired more easily than I used to.  
2 I get tired from doing almost anything.  
3 I am too tired to do anything.  
 
18.  0 My appetite is no worse than usual.  
1 My appetite is not as good as it used to be.  
2 My appetite is much worse now.  
3 I have no appetite at all anymore.  
 





1 I have lost more than five pounds.  
2 I have lost more than ten pounds.  
3 I have lost more than fifteen pounds. 
 
20.  0 I am no more worried about my health than usual.  
1 I am worried about physical problems like aches, pains, upset stomach, or constipation.  
2 I am very worried about physical problems and it's hard to think of much else.  
3 I am so worried about my physical problems that I cannot think of anything else.  
 
21.  0 I have not noticed any recent change in my interest in sex.  
1 I am less interested in sex than I used to be.  
2 I have almost no interest in sex.  





Appendix X. Skewness, Kurtosis, and Shapiro-Wilk Values for Study Variables 









         
PSS -0.148 (0.271) 0.546 0.982 (0.345) -0.555 (0.535) -1.037 
STAI-State 0.565 (0.271) 2.085* 0.961 (0.016)** -0.238 (0.535) -0.445 
STAI-Trait 0.065 (0.271) 0.240 0.968 (0.045)** -1.050 (0.535) -2.804* 
BDI 0.692 (0.271) 2.553* 0.953 (0.006)** 0.138 (0.535) 0.258 
      
DHA 0.616 (0.271) 2.273* 0.967 (0.041)** 0.080 (0.535) 0.150 
EPA 1.667 (0.271) 6.151* 0.887 (0.000)** 4.914 (0.535) 9.185* 
ALA 1.172 (0.271) 4.325* 0.919 (0.000)** 1.703 (0.535) 3.183* 
Omega-3 Index 0.849 (0.271) 3.133* 0.952 (0.005)** 1.054 (0.535) 1.970 
      
IL-1β 5.828 (0.271) 21.506* 0.442 (0.000)** 41.627 (0.535) 77.807* 
IL-6 4.792 (0.271) 17.683* 0.383 (0.000)** 24.087 (0.535) 45.022* 
IL-8 2.895 (0.271) 10.683* 0.696 (0.000)** 10.264 (0.535) 19.185* 
TNF-α 8.597 (0.271) 31.723* 0.151 (0.000)** 75.321 (0.535) 140.787* 
      
Lactobacillus 4.865 (0.293) 16.604* 0.357 (0.000)** 25.707 (0.578) 44.476* 
Bifidobacterium 2.242 (0.293) 7.652* 0.721 (0.000)** 5.510 (0.578) 9.533* 
      
* Z-score is <-2 or >2 















Appendix Y. Comparison of square root and logarithmic transformation of skewed independent 
variables 
Square Root Transformation 









BDI -0.085 (0.271) -0.314 0.984 (0.408) -0.537 (0.535) -1.004 
STAI-State 0.277 (0.271) 1.022 0.977 (0.169) -0.557 (0.535) -1.041 
STAI-Trait -0.127 (0.271) 0.469 0.969 (0.054)** -0.972 (0.535) -1.817 
      
DHA 0.303 (0.271) 1.118 0.985 (0.461) -0.381 (0.535) -0.712 
EPA 0.813 (0.271) 3.000* 0.962 (0.18)** 1.597 (0.535) 2.985* 
ALA 0.656 (0.271) 2.421* 0.963 (0.023)** 0.816 (0.535) 1.525 
Omega-3 Index 0.561 (0.271) 2.070* 0.972 (0.076) 0.223 (0.535) 0.417 
      
IL-1β 2.577 (0.271) 9.509* 0.792 (0.000)** 10.788 (0.535) 20.164* 
IL-6 3.301 (0.271) 12.181* 0.648 (0.000)** 12.978 (0.535) 24.258* 
IL-8 1.450 (0.271) 5.351* 0.895 (0.000)** 3.259 (0.535) 6.092* 
TNF-α 6.524 (0.271) 24.074* 0.402 (0.000)** 49.783 (0.535) 93.052* 
      
Lactobacillus 2.748 (0.293) 9.379* 0.673 (0.000)** 8.949 (0.578) 15.483* 
Bifidobacterium 0.824 (0.293) 2.812* 0.931 (0.001)** 0.261 (0.578) 0.452 
      
* Z-score is <-2 or >2 
**Shaprio-Wilk < 0.05 
 
Logarithmic Transformation 









BDI -1.000 (0.271) -3.690* 0.918 (0.000)** 0.595 (0.535) 1.112 
STAI-State -0.007 (0.271) -0.026 0.982 (0.345) -0.688 (0.535) -1.286 
STAI-Trait -0.337 (0.271) -1.244 0.964 (0.025)** -0.753 (0.535) -1.407 
      
DHA 0.001 (0.271) 0.004 0.990 (0.795) -0.548 (0.535) -1.024 
EPA 0.050 (0.271) 0.185 0.990 (0.788) 0.540 (0.535) 1.009 
ALA 0.069 (0.271) 0.255 0.983 (0.317) 0.773 (0.535) 1.445 
Omega-3 Index 0.306 (0.271) 1.129 0.984 (0.409) -0.279 (0.535) -0.521 





IL-1β 0.124 (0.271) 0.458 0.990 (0.814) 0.410 (0.535) 0.766 
IL-6 1.006 (0.271) 3.712* 0.934 (0.001)** 2.518 (0.535) 4.707* 
IL-8 0.058 (0.271) 0.214 0.986 (0.534) 0.275 (0.535) 0.514 
TNF-α 1.256 (0.271) 4.635* 0.925 (0.000)** 4.647 (0.535) 8.686* 
      
Lactobacillus -0.250 (0.293) -0.853 0.954 (0.014)** -0.876 (0.578) -1.521 
Bifidobacterium -1.164 (0.293) -3.973* 0.929 (0.001)** 2.172 (0.578) 3.758* 
      
* Z-score is <-2 or >2 













































Table 1. Demographic Characteristics (N = 79) 
Characteristics  M ± SD or N (%) 
Age, years 21.7 ± 4.1 
Gender  
     Female 79 (100.0) 
Ethnicity  
     Black 20 (25.3) 
     White 19 (24.1) 
     Hispanic/Latino 19 (24.1) 
     Asian/Pacific Islander 12 (15.2) 
     Mixed 6 (7.6) 
     Other 3 (3.8) 
Household Income  
     Less than $25,000 27 (34.2) 
     $25,000-$34,999 9 (11.4) 
     $35,000-$49,999 13 (16.5) 
     $50,000-$74,999 16 (20.3) 
     $75,000-$99,999 4 (5.1) 
     $100,000-$149,999 3 (3.8) 





Table 2. Descriptive Statistics of Self-Report Measures (N = 79) 
Measure  M ± SD Range (Median) 
PSS 20.0 ± 6.6 6.0 - 34.0 (20.0) 
STAI-State 37.4 ± 10.8 20.0 – 67.0 (37.0) 
STAI-Trait 44.9 ± 11.3 23.0 – 68.0 (45.0) 
BDI 12.5 ± 8.0 1.0 – 35.0 (11.0) 
Note. BDI = Beck Depression Inventory, PSS = Perceived Stress Scale, 
STAI-State = State-Trait Anxiety Inventory-State, STAI-Trait = State-









Table 3. Mean and Standard Deviations for Biological 
Measures   
Measure  M ± SD 
Omega-3 Level  
 
DHA 2.69 ± 0.75 
EPA 0.49 ± 0.21 
ALA 0.50 ± 0.17 
ω-3 Index 4.93 ± 1.03 
  
Inflammatory Markers   
IL-1β 135.0 ± 238.6 
IL-6 4.7 ± 9.0 
IL-8 725.9 ± 681.0 
TNF-α 7.8 ± 37.9 
  
Gut Bacteria   
Lactobacillus 0.81 ± 0.30  
Bifidobacterium 2.56 ± 0.43  
Note. For gut bacteria results = (n = 67). ALA = Alpha-
linolenic Acid, DHA = Docosahexaenoic Acid, EPA = 
Eicosapentaenoic Acid, IL-1β = Interleukin-1 Beta, IL-6 = 
Interleukin-6, IL-8 = Interleukin-8, TNF-α = Tumor Necrosis 








Table 4. Spearman Correlations of ω-3 Levels and Self-report Measures (N = 79) 








PSS -0.19 (0.09) -0.21 (0.06) -0.07 (0.52) -0.01 (0.92) 
STAI-State -0.08 (0.47) -0.09 (0.46) -0.03 (0.79) -0.09 (0.42) 
STAI-Trait -0.29 (0.01)* -0.30 (0.01)* -0.18 (0.12) 0.04 (0.71) 
BDI -0.20 (0.07) -0.21 (0.06) -0.13 (0.24) -0.08 (0.47) 
*p<0.05 
Note. ALA = Alpha-linolenic Acid, BDI = Beck Depression Inventory, DHA = Docosahexaenoic 
Acid, EPA = Eicosapentaenoic Acid, PSS = Perceived Stress Scale, STAI-State = State-Trait 








Table 5. Spearman Correlations of ω-3 Levels and Inflammatory Markers (N = 79) 








IL-1β -0.26 (0.02)* -0.24 (0.03)* -0.20 (0.08) -0.05 (0.65) 
IL-6 -0.10 (0.39) -0.14 (0.22) -0.01 (0.95) 0.06 (0.59) 
IL-8 -0.14 (0.23) -0.14 (0.21) -0.11 (0.34) -0.02 (0.84) 
TNF-α -0.16 (0.17) -0.15 (0.18) -0.11 (0.35) -0.02 (0.90) 
*p<0.05 
Note. ALA = Alpha-linolenic Acid, DHA = Docosahexaenoic Acid, EPA = Eicosapentaenoic 
Acid, IL-1β = Interleukin-1 Beta, IL-6 = Interleukin-6, IL-8 = Interleukin-8, TNF-α = Tumor 










Table 6. Spearman Correlations of ω-3 Levels and Gut Bacteria Abundance (N = 67) 








Lactobacillus -0.13 (0.29) -0.09 (0.45) -0.10 (0.40) 0.06 (0.65) 
Bifidobacterium -0.02 (0.89) -0.01 (0.96) -0.02 (0.88) -0.09 (0.47) 
Note. ALA = Alpha-linolenic Acid, DHA = Docosahexaenoic Acid, EPA = Eicosapentaenoic 







Table 7. Spearman Correlations of Gut Bacteria and 
Self-report Measures (N = 67) 




PSS -0.02 (0.89) 0.11 (0.37) 
STAI-State -0.05 (0.71) 0.16 (0.20) 
STAI-Trait -0.01 (0.96) 0.17 (0.16) 
BDI 0.03 (0.84)      0.16 (0.21) 
Note. BDI = Beck Depression Inventory, PSS = Perceived 
Stress Scale, STAI-State = State-Trait Anxiety Inventory-

















PSS 0.21 (0.07) 0.15 (0.19) 0.07 (0.57) 0.05 (0.67) 
STAI-State 0.14 (0.23) -0.05 (0.67) -0.05 (0.67) -0.02 (0.89) 
STAI-Trait 0.17 (0.13) 0.07 (0.55) 0.06 (0.62) 0.03 (0.80) 
BDI 0.26 (0.02)* 0.17 (0.14) 0.14 (0.23) 0.11 (0.34) 
*p<0.05 
Note. BDI = Beck Depression Inventory, IL-1β = Interleukin-1 Beta, IL-6 = Interleukin-6, IL-8 = 
Interleukin-8, PSS = Perceived Stress Scale, STAI-State = State-Trait Anxiety Inventory-State, 













Table 9. Spearman Correlations of Gut Bacteria and 
Inflammation (N = 67) 




IL-1β 0.11 (0.36) -0.01 (0.96) 
IL-6 -0.05 (0.67) -0.05 (0.69) 
IL-8 0.13 (0.31) 0.09 (0.45) 
TNF-α 0.09 (0.50) -0.04 (0.75) 
Note.IL-1β = Interleukin-1 Beta, IL-6 = Interleukin-6, IL-









†p<0.10, *p<0.05, **p<0.01  
Note. Bifido = Bifidobacterium, IE = Indirect Effect of the serial mediation, IL-1β = Interleukin-
1 Beta, IL-6 = Interleukin-6, IL-8 = Interleukin-8, Lacto = Lactobacillus, PSS = Perceived Stress 











Table 10. Unstandardized Path Coefficients (standard error) for Serial Mediation Model of 








































































































































































†p<0.10, *p<0.05, **p<0.01  
Note. Bifido = Bifidobacterium, DHA = Docosahexaenoic Acid, IE = Indirect Effect of the serial 
mediation, IL-1β = Interleukin-1 Beta, IL-6 = Interleukin-6, IL-8 = Interleukin-8, Lacto = 
Lactobacillus, PSS = Perceived Stress Scale, TNF-α = Tumor Necrosis Factor Alpha. 95 % CIs = 






Table 11. Unstandardized Path Coefficients (standard error) for Serial Mediation Model of 







































































































































































†p<0.10, *p<0.05, **p<0.01  
Note. Bifido = Bifidobacterium, EPA = Eicosapentaenoic Acid, IE = Indirect Effect of the serial 
mediation, IL-1β = Interleukin-1 Beta, IL-6 = Interleukin-6, IL-8 = Interleukin-8, Lacto = 
Lactobacillus, PSS = Perceived Stress Scale, TNF-α = Tumor Necrosis Factor Alpha. 95 % CIs = 






Table 12. Unstandardized Path Coefficients (standard error) for Serial Mediation Model of 








































































































































































†p<0.10, *p<0.05, **p<0.01  
Note. ALA = Alpha-linolenic Acid, Bifido = Bifidobacterium, IE = Indirect Effect of the serial 
mediation, IL-1β = Interleukin-1 Beta, IL-6 = Interleukin-6, IL-8 = Interleukin-8, Lacto = 
Lactobacillus, PSS = Perceived Stress Scale, TNF-α = Tumor Necrosis Factor Alpha. 95 % CIs = 












































































































































































†p<0.10, *p<0.05, **p<0.01  
Note. Bifido = Bifidobacterium, IE = Indirect Effect of the serial mediation, IL-1β = Interleukin-
1 Beta, IL-6 = Interleukin-6, IL-8 = Interleukin-8, Lacto = Lactobacillus, STAI-Trait = State-
Trait Anxiety Inventory-Trait, TNF-α = Tumor Necrosis Factor Alpha. 95 % CIs = the upper and 




Table 14. Unstandardized Path Coefficients (standard error) for Serial Mediation Model of 







































































































































































†p<0.10, *p<0.05, **p<0.01  
Note. Bifido = Bifidobacterium, DHA = Docosahexaenoic Acid, IE = Indirect Effect of the serial 
mediation, IL-1β = Interleukin-1 Beta, IL-6 = Interleukin-6, IL-8 = Interleukin-8, Lacto = 
Lactobacillus, STAI-Trait = State-Trait Anxiety Inventory-Trait, TNF-α = Tumor Necrosis 





Table 15. Unstandardized Path Coefficients (standard error) for Serial Mediation Model of 







































































































































































†p<0.10, *p<0.05, **p<0.01  
Note. Bifido = Bifidobacterium, EPA = Eicosapentaenoic Acid, IE = Indirect Effect of the serial 
mediation, IL-1β = Interleukin-1 Beta, IL-6 = Interleukin-6, IL-8 = Interleukin-8, Lacto = 
Lactobacillus, STAI-Trait = State-Trait Anxiety Inventory-Trait, TNF-α = Tumor Necrosis 












































































































































































†p<0.10, *p<0.05, **p<0.01  
Note. ALA = Alpha-linolenic Acid, Bifido = Bifidobacterium, IE = Indirect Effect of the serial 
mediation, IL-1β = Interleukin-1 Beta, IL-6 = Interleukin-6, IL-8 = Interleukin-8, Lacto = 
Lactobacillus, STAI-Trait = State-Trait Anxiety Inventory-Trait, TNF-α = Tumor Necrosis 




Table 17. Unstandardized Path Coefficients (standard error) for Serial Mediation Model of 







































































































































































†p<0.10, *p<0.05, **p<0.01  
Note. BDI = Beck Depression Inventory, Bifido = Bifidobacterium, IE = Indirect Effect of the 
serial mediation, IL-1β = Interleukin-1 Beta, IL-6 = Interleukin-6, IL-8 = Interleukin-8, Lacto = 




Table 18. Unstandardized Path Coefficients (standard error) for Serial Mediation Model of 







































































































































































†p<0.10, *p<0.05, **p<0.01  
Note. BDI = Beck Depression Inventory, Bifido = Bifidobacterium, DHA = Docosahexaenoic 
Acid, IE = Indirect Effect of the serial mediation, IL-1β = Interleukin-1 Beta, IL-6 = Interleukin-
6, IL-8 = Interleukin-8, Lacto = Lactobacillus, TNF-α = Tumor Necrosis Factor Alpha. 95 % CIs 




Table 19. Unstandardized Path Coefficients (standard error) for Serial Mediation Model of 







































































































































































†p<0.10, *p<0.05, **p<0.01  
Note. BDI = Beck Depression Inventory, Bifido = Bifidobacterium, EPA = Eicosapentaenoic 
Acid, IE = Indirect Effect of the serial mediation, IL-1β = Interleukin-1 Beta, IL-6 = Interleukin-
6, IL-8 = Interleukin-8, Lacto = Lactobacillus, TNF-α = Tumor Necrosis Factor Alpha. 95 % CIs 
= the upper and lower 95 % confidence intervals. 
 
  








































































































































































†p<0.10, *p<0.05, **p<0.01  
Note. ALA = Alpha-linolenic Acid, BDI = Beck Depression Inventory, Bifido = 
Bifidobacterium, IE = Indirect Effect of the serial mediation, IL-1β = Interleukin-1 Beta, IL-6 = 
Interleukin-6, IL-8 = Interleukin-8, Lacto = Lactobacillus, TNF-α = Tumor Necrosis Factor 













































































































































































Figure 1. Inflammation as a hypothesized mechanism of action explaining the relationship 















Figure 2. Proposed path analysis examining inflammation and gut bacteria as a hypothesized 


















Figure 3. Proposed path analysis examining inflammation and gut bacteria as a hypothesized 



















Figure 4. Proposed path analysis examining inflammation and gut bacteria as a hypothesized 















Figure 5. Proposed serial mediation model, key for mediation results in Aim 2.  
 
